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ABSTRACT 
The impact of tumor associated stromal cells in tumor formation, 
progression, and response to therapy has led to a paradigm shift in cancer 
therapy. For many years, tumors were considered as a mass consisting only of 
actively proliferating cancer cells and therapies were design to target these cells. 
However, research in the last two decades has shown that tumors are not only 
comprised of a heterogeneous population of neoplastic cells, but they are also 
comprised of and infiltrated by a heterogeneous population of non-tumor cells 
that contribute to tumor progression and potentially affect the efficacy of tumor-
directed chemotherapies. Tumors are now considered as complex organ 
consisting of both cancerous and noncancerous cells interacting with each other 
within the tumor microenvironment to promote malignancy.  
For decades, 5- fluorouracil (5-FU), an inhibitor of the enzyme thymidylate 
synthase (TS), has been used in the clinical management of colorectal cancer. 
Although it has been beneficial to some patients, its use has been severely 
limited by cytotoxic side effects due to its lack of specificity, affecting both rapidly 
proliferating cancer and healthy normal cells, and acquired resistance by cancer 
cells over time. To circumvent these limitations, we propose that genetic 
modulation of non-tumor or stromal cells in the microenvironment might enhance 
drug efficacy and reduce drug-induced cytotoxicity. 
 vii 
Genetic modulation of stromal cells may be accomplished by utilizing 
ribonucleic acid interference (RNAi) technologies. With RNAi, we were able to 
suppress intracellular protein levels of TS prior to therapy and chemo-sensitized 
cells to TS inhibitors. In vivo, we found that the use of constitutive H1 promoter 
RNAi vector systems to sensitize hematopoietic stem cells in ApcMin/+ mice, was 
problematic and toxic. However, using a mCMV constitutive RNAi vector which 
was not toxic in an in vivo model system, we found that we can sensitize stromal 
cells to the cytotoxic effects of 5-FU. To specifically direct chemo-sensitivity to 5-
FU to cells in the tumor microenvironment we utilized the promoter of 
osteopontin, a gene that was only upregulated in hematopoietic cells in the tumor 
microenvironment, to drive the expression of a TS silencing shRNA. This allowed 
us to enhance chemo-sensitivity to 5-FU specifically within the tumor stroma. 
In addition to enhancing the efficacy of TS inhibitors by modulating bone 
marrow derived cells, we also targeted mast cells by incorporating a 
pharmacological drug, Cromolyn that inhibits mast cells function, and combined 
this with 5-FU therapy. We had previously found that mast cells are resistant to 
5-FU and are recruited into the tumor microenvironment upon systemic treatment 
of ApcMin/+ mice with 5-FU.  We hypothesized that inhibition of mast cells in 
combination with 5-FU treatment might enhance anti-tumor efficacy of 5-FU or 
block the recurrence of tumors post-therapy. The results showed that 
administration of Cromolyn after systemic treatment with 5-FU decreased 
recurrence of tumor post therapy. These findings suggest that modulation of the 
tumor stromal cells by genetic modification or by pharmacological methods have 
 viii 
the potential to enhance the anti-tumor efficacy of TS inhibitors. It will be 
necessary to assess the long-term effects and the mechanistic underpinnings of 
these studies to realize their clinical utility.  
 ix 
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CHAPTER 1 
INTRODUCTION 
1.1 COLON CANCER 
In 2014, the American Cancer Society estimated that approximately 136,830 
individuals were diagnosed with colorectal cancer (CRC) and approximately 
50,310 will die from this disease. CRC is the third most diagnosed and the 
second cause of cancer related deaths in the United States. CRC begins with the 
development of polyps in the colon or large intestines, with low incidents 
occurring in the small intestines. Studies have shown that the formation of polyps 
normally occur in a period of ten to twenty years, during which a non-cancerous 
 
Figure 1.1: Stages of Colorectal Cancer: Progression of polyp development into cancer 
on the lining of the intestinal wall.  (Johns Hopkins Cancer Center, Internet) 
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growth forms on the inner lining of the colon or the large intestine (Stryker, Wolff 
et al. 1987; Winawer and Zauber 2002). These non-cancerous adenomatous 
polyps are likely to become cancerous upon continuous growth, developing into 
an adenocarcinoma, a malignant tumor of glandular cells (Figure 1.1). The 
progression from adenomatous polyps to adenocarcinomas is the result of 
mutations, which occur in tumor suppressor genes such as the adenomatous 
polyposis coli (APC) and tumor protein p53 (TP53). Mutation of the APC gene 
occurs in the early stage of CRC development, and is responsible for familial 
adenomatous polyposis (FAP), an inherited form of CRC (Jasperson, Tuohy et 
al. 2010). The APC gene encodes a multifunctional protein that regulates the 
expression of β-catenin in the Wnt signaling pathway, cell adhesion, proliferation, 
and apoptotic pathways (Coppede, Lopomo et al. 2014). Typically, the APC 
protein forms a cytoplasmic complex with other proteins in the Wnt signaling 
pathway. This complex targets β-catenin by ubiquitination for proteasome 
degradation keeping its intracellular levels low. Conversely, loss of APC function 
causes accumulation of β-catenin in the cytoplasm, and its translocation into the 
nucleus where it assists in the activation of genes essential for cell proliferation, 
resulting in abnormal growth and adenomatous polyps. 
Mutations in TP53 typically occur after the APC mutation, as the polyp 
continues to grow and become cancerous. TP53 is a nuclear protein that initiates 
cell cycle arrest to initiate repair or apoptosis in response to DNA damage 
(Vogelstein, Lane et al. 2000). Loss of TP53 function, which is critical for sensing 
and repairing damaged DNA, allows cancerous cells to escape the cell cycle 
  
3 
checkpoint and proceed with unregulated cell division to produce daughter cells 
with mutated DNA. This mutation promotes the transition from an adenomatous 
polyp to an adenocarcinoma.  
Approximately 96% of colorectal cancers are adenocarcinomas (Stewart, 
Wike et al. 2006). Common symptoms include bleeding from the rectum, 
discomfort in the lower abdomen, constipation and diarrhea, and loss of appetite. 
Fortunately, early screening via a colonoscopy allows visual examination of the 
colon so that adenomas or adenocarcinomas can be excised from the colon and 
large intestine. Although the advancement of colonoscopies has increased CRC 
survival (Edwards, Ward et al. 2010), there is room for improvement to decrease 
of CRC related deaths. To date, the 5-year survival rate is approximately 89.9% 
for localized CRC, 70.5% when CRC spreads to regional lymph nodes, and 
12.9% if CRC has metastasized to distant organs (Surveillance, Epidemiology, 
and the End Results (SEER) Program).  The majority of CRC related deaths 
result from metastatic CRC cells entering into the lymph nodes and blood 
vessels, and spreading to distant organs such as the liver and/or lungs.  Current 
treatments are not efficient in blocking this process. In addition, contributing to 
the inadequacies of our anti-cancer treatments is the reoccurrence of the cancer 
with more aggressive properties, or the development of resistance against 
chemotherapy, such as 5-Fluorouracil (5-FU) that is commonly used to treat 
CRC. Thus, in order to combat and eliminate this disease, it is important to 
develop new anti-cancer therapies or utilize current anti-cancer therapies in 
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combination with novel therapies to enhance their efficacy while minimizing their 
toxicities.  
 
1.2  HALLMARKS OF CANCER 
 In order develop effective anti-cancer therapies and to resolve the 
problematic side effects resulting from their lack of specificity for cancer cells, it is 
important to understand the complexity of cancer development. Currently, eight 
properties define the hallmark of cancer cells. These properties provide a 
framework for the development of novel therapies. These hallmark properties 
include: sustaining proliferative signaling, evading growth suppressors, resisting 
cell death, enabling replicative immortality, inducing angiogenesis, activating 
invasion and metastasis, reprogramming of energy metabolism, and evading 
immune destruction (Hanahan and Weinberg 2011). The unregulated production 
of growth signals provides cancer cells the ability to acquire the hallmark of 
sustained proliferative signaling. This causes an imbalance in homeostasis, 
wherein cancer cells uncontrollably produce growth factors for themselves. 
However, it is not sufficient for cancer cells sustain proliferation because cellular 
checkpoints within cell division can inhibit the continuous growth necessary to 
develop a tumor mass. Thus, obtaining the ability to evade the regulation of 
growth suppressors, through mechanisms such as TP53 is necessary for tumor 
progression. Growth suppressors negatively regulate cell proliferation contingent 
on DNA abnormalities and the lack of normalcy due to stress caused by 
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nucleotide, oxygen, and energy levels within or outside the cell. Mutations in 
growth suppressors disrupt induced apoptosis.  
 Alternatively, the cancer cell’s quest for survival may also increase the 
expression of anti-apoptotic regulators that contribute to resistance to apoptosis. 
Under normal conditions, the balance of pro- and anti- apoptotic proteins 
regulates programmed cell death. The abnormalities in cancer cells creates 
imbalance in favor of inhibiting the trigger of death. Resisting cell death does not 
guarantee cancer cells the ability for unlimited proliferation, but obtaining the 
hallmark of immortality does. Immortality is achieved by up regulating the 
expression of telomerase, an enzyme responsible for elongating telomeres, 
resulting in extended protection of chromosomal DNA. With each cell division, 
the telomere length decreases, until it reaches a point at which the cell goes into 
a silencing phrase or program cell death. Hence, immortality ensures the tumors 
capability to expand. However, as the tumor expands it must ensure the ability to 
sustain a healthy environment to maintain its growth. Tumor progression requires 
sources of energy, the import of nutrients, and the export of waste, which is 
accomplished by increasing energy metabolism and inducing angiogenesis. The 
newly discovered hallmark of reprogramming energy metabolism allows cancer 
cells to survive by up regulating the transport of glucose into the cell where it is 
broken down to generate energy and metabolites to compensate for the increase 
in cell growth and division.  Angiogenesis is the process of developing new blood 
vessels from existing vessels that allow the import and export of the necessary 
nutrients and waste. The ability to induce angiogenesis sustains the growth of the 
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tumor in a localized region; however, the ability to travel to another organ 
requires the activation of invasion and metastatic characteristics. Normally 
aggressive cancers alter the expression of cell-to-cell adhesion molecules; giving 
cancer cells the capacity to invade nearby blood vessels in an attempt to spread 
to a distal organ. The accomplishment of metastasizing to a distal organ is 
contingent on the cancer cell’s ability to detached from the primary tumor, survive 
in circulation, extravagate and adapt to the microenvironment of the distal organ 
to survive. Finally, the property of evading immune surveillance is a significant 
hallmark that allows cancer cells to avoid destruction by the immune system, 
which served to eliminate rogue cells. Delineation of these hallmark properties 
has provided clarity to cancer development and its capability to resist therapies. 
Cancer research has evolved from the perspective of exclusively targeting and 
understanding the development of neoplastic cells, to the forefront of studying 
the intricate relationship that develops between both neoplastic and non-
neoplastic cells derived from bone marrow to create the tumor microenvironment 
(TME).  
 
1.3 TUMOR MICROENVIROMENT  
 Since the recognition of the TME, a paradigm shift in cancer therapy has 
occurred, such that the tumor is perceived to be an organ or complex tissue 
(Egeblad, Nakasone et al. 2010), composed of a heterogeneous populations of 
both malignant and non-malignant cells and extracellular matrix, which function 
abnormally to promote and sustain a pro-tumorigenic environment, i.e. the 
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hallmarks of cancer (Coussens and Werb 2002; Chantrain, Feron et al. 2008; 
Whiteside 2008; Hanna, Quick et al. 2009; Peddareddigari, Wang et al. 2010; 
Hanahan and Coussens 2012). This heterogeneous population of non-malignant 
cells within a tumor includes, but is not limited to the following cells: tumor 
associated macrophages (TAMs); myeloid derived suppressor cells (MDSCs), 
mast cells, and cancer associate fibroblasts (CAFs), monocytes, endothelial 
cells, and neutrophils (Figure 1.2).The TME has the potential to activate TAMs 
into two subgroups: M1 (anti-tumor) or M2 (pro-tumor) macrophages (Gordon 
 
 
 
 
Figure 1.2: Tumor Microenvironment: Infiltration of bone marrow derived cells into 
the tumor microenvironment (TME). The tumor stroma is comprised of many immune 
cells that influence the tumor response to anti-cancer therapies.  
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2003; Mantovani, Sica et al. 2007). MDSCs have been shown to cooperate in the 
non-responsiveness of T-cells to promote tumorigenesis (Nagaraj and 
Gabrilovich 2008). Mast cells exhibit the ability to secrete many pro-tumorigenic 
growth stimulatory factors, which can trigger the angiogenic switch to turn on 
angiogenesis (Coussens, Raymond et al. 1999). In response to tumor growth, 
CAFs are secrete a host of growth factors such as the epidermal growth factor 
(EGF), transforming growth factor beta (TGF-β), and hepatocyte growth factor 
(HGF) (Kalluri and Zeisberg 2006). These non-cancerous cells provide a pro-
inflammatory environment by secreting cytokines, chemokines, and growth 
factors essential for the initiation and maintenance of tumor growth. In addition to 
the infiltration of these heterogeneous population of cells within the tumor, the 
composition of the extracellular matrix, for example, laminin, collagen, 
fibronectin, and proteoglycans can promote tumor progression (Peddareddigari, 
Wang et al. 2010) and provide resistance to drug therapies due to abnormal 
tissue organization that provides a hindrance to drug delivery (Egeblad, 
Nakasone et al. 2010). For example, type 1collagen plays a significant role in 
regulating tumor sensitivity to various anti-neoplastic therapies (Loeffler, Kruger 
et al. 2006).  
 These examples represent minuscule information on the intricate 
relationship between cancer and non-cancerous cells. These studies confirm that 
the neoplastic cells are not solely acting alone, but they collaborate and co-
evolve with various immune cells to orchestrate tumor growth and development. 
These tumorigenic properties increase as the tumor matures causing 
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morphological changes to occur within the TME to become supportive.  Hence 
advanced stages of cancer exhibit altered tumorigenic properties in comparison 
to the early stages of cancer.  The roles of these immune cells need intense 
investigation, to have a better understanding of the supportive role of the TME at 
the different stages of tumor development. In addition, this will contribute to the 
knowledge of how the TME provides protection against chemotherapies, 
providing insight into the development of more effective ways to target the tumor.  
 
1.4 THE ROLE OF MAST CELLS  IN TUMOR BIOLOGY 
 As previously described, the TME consists of bone marrow derived cells 
that contribute to tumor formation and potentially play a vital role in resistance to 
current chemotherapies. In particular, there is a growing interest in the role of 
mast cells in cancer development, and recent studies have identified functions of 
these cells in tumor biology. Historically, mast cells are typically associated with 
immunoglobulin E (IgE)-mediated response to an allergic reaction or an 
asthmatic incident. The IgE mediated response causes the activation of mast cell 
degranulation, which results in the crosslinking of antigens and IgE molecules 
that are bound to the high affinity receptors, FC epsilon RI (FcεRI) located on the 
cell surface of mast cells (Gould, Sutton et al. 2003). This immune response 
provokes inflammation resulting in recruitment and activation of additional 
immune cells to the local site. Thus, mast cells are effectors cells that exert 
immune signals to regulate and recruit other immune cells. These granulocytes 
cells are subdivided into two subgroups; mucosal and connective mast cells. The 
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differences between the subgroups is dependent the content of granules, which 
occurs during maturation. Mast cell precursors are released from the bone 
marrow as immature cells and migrate into various tissues within the body to 
undergo maturation and differentiation. Maturation and differentiation influenced 
by the infiltrated tissue environment resulting in a heterogeneous population of 
mast cells throughout the body. Mast cell granules have three subgroups: pre-
formed granules, de novo synthesized granules, and cytokines and chemokines. 
The pre-formed granules include histamine, heparin, and the proteases tryptase, 
chymase, and carboxypeptidase A3 (CPA3). The second group is the de novo 
synthesized lipid mediators, which includes: LTC4 and PGD2, and  the third 
category consists of the various cytokines and chemokines, such as but not 
limited to tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), and matrix metallopeptidase-9 (MMP9) 
(Theoharides, Kempuraj et al. 2007). Upon degranulation, the pre-formed 
granule mediators are immediately release within minutes; while the de novo 
synthesized mediators are released slowly within a period of three to twelve 
hours later. In addition, the mechanism for releasing the mediators can occur by 
either complete or selective degranulation (Dvorak and Kissell 1991; 
Theoharides and Kalogeromitros 2006). The role of mast cells in tumor formation 
and immunity is poorly understood, and accumulating evidence has shown 
controversial roles in tumor biology. Mast cells can either display anti-tumor or 
pro-tumor responses depending on the type of cancer and the stage of the tumor 
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development (Groot Kormelink, Abudukelimu et al. 2009; Ribatti 2013; Oldford 
and Marshall 2014). 
 Mast cells have been shown to mediate anti-tumor response to cancer in 
in vivo model systems. In ApcMin/+mice, a model of colon carcinogenesis, genetic 
ablation of mast cells resulted in larger and increased number of intestinal tumors 
compared to wild type littermates, suggesting that mast cells can suppress 
intestinal tumor development (Sinnamon, Carter et al. 2008). In addition, several 
studies suggest that IgE mediated activation of mast cells within tumor results in 
an anti-tumor immune response (Jensen-Jarolim, Achatz et al. 2008; Teo, Utz et 
al. 2012; Singer and Jensen-Jarolim 2014). Mast cells can also regulate the 
activity of immune cells. For example, mast cells can promote recruitment of 
MDSCs into the tumor and activate their expression of IL-17, which in turn 
mobilizes and suppresses the pro-tumorigenic activity of T-regulatory cells within 
the tumor. Collectively, these studies suggest that mast cells induce anti-tumor 
responses and play a role in promoting inflammation to recruit additional 
leukocytes into the tumor region where they activate or regulate immune cell 
activity and induce cytotoxic activity. 
 Alternatively, mast cells can display a pro-tumorigenic response. Studies 
have shown that pro-inflammatory mediators from mast cells can promote tumor 
proliferation and provide a suitable environment to sustain tumor growth and 
development. Gounaris and colleagues showed that mast cells for polyp 
development in ApcMin/+mice (Gounaris, Erdman et al. 2007). In addition poor 
prognosis has been correlated to high tumor infiltration of mast in many human 
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cancers such as melanoma, lung, gastric, colorectal, and prostate carcinomas 
(Groot Kormelink, Abudukelimu et al. 2009). An in vitro study utilizing the human 
mast cell line, LAD2 demonstrated the capacity of mast cells to regulate the 
invasiveness of cervical cancer cells, yet cervical cancer cells were able to 
stimulate the degranulation of mast cells, suggesting an intimate communication 
between tumor and inflammatory immune cells (Rudolph, Boza et al. 2008). 
Another study using a HPV16 transgenic mouse model of squamous cell 
epithelial carcinoma showed that chymase released from tumor infiltrating mast 
cells activated MMP9 resulting in extracellular remodeling (Coussens, Raymond 
et al. 1999). This study also demonstrated that mast cells infiltrated tumors prior 
to the angiogenic switch. To validate the role of mast cells in angiogenesis and 
tumor remodeling, another study using a Myc-induced pancreatic islet tumor 
model showed infiltration of mast cells within twenty-four hours of Myc activation.  
The recruitment of mast cells resulted in the expansion of Myc-induced tumors 
(Soucek, Lawlor et al. 2007). Together, these studies show that mast cells 
perform pro-tumorigenic roles by contributing to tumor remodeling, angiogenesis, 
and immune suppression. 
 The pro-tumorigenic roles of mast cells affect the efficacy of anti-cancer 
therapies by contributing to tumor progression and assisting in tumor remodeling 
and tumor sustainability. Currently, the efficacy of anti-cancer therapies is 
dependent on its direct deliverable contact with cancer cells within the tumor 
where its cytotoxic action can destroy or reduce tumor burden. However, tumor 
remodeling can inhibit delivery of anti-cancer therapies to promote relapse. It is 
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important to decipher the pro-tumorigenic roles of mast cells to develop 
strategies to enhance the efficacy of anti-cancer therapies. 
1.5 THYMIDYLATE SYNTHASE AND ITS INHIBITOR  5-FU 
 Thymidylate synthase (TS) is an enzyme that catalyzes the reductive 
methylation of 2’ deoxyuridine- 5’ monophosphate (dUMP) to 2’ deoxythymidine- 
5’-monophosphate (dTMP) and dihydrofolate using 5,10-methylenetetrahydro-
folate (CH2THF) as a methyl donor (Danenberg 1977; Carreras and Santi 1995). 
Subsequently, dTMP is sequentially phosphorylated into 2’-deoxythimdine– 
5’diphosphate (dTDP), and then into 2’ deoxythmidine- 5’ triphosphate (dTTP), 
an essential component for DNA replication and repair in actively proliferating 
cells. Importantly, this pathway provides the sole intracellular source of dTTP, 
thus, TS has been an important target of chemotherapeutic agents. In addition to 
its catalytic function, TS is an auto-regulatory protein that binds to its mRNA to 
repress its translation and has been shown to interact with the mRNAs of TP53 
and c-myc (Chu and Allegra 1996). TS inhibition results in depletion of dTMP and 
accumulation of dUMP leading to increased levels of deoxyuridine triphosphate 
(dUTP) that is mis-incorporated into DNA, resulting in DNA fragmentation and 
ultimately cell apoptosis (Longley, Harkin et al. 2003; Garg, Henrich et al. 2010).  
TS inhibitors are typically substrate analogs or analogs of the folate co-factor.  
The most widely used TS inhibitor is the 5-FU, a fluoropyrimidine that has been 
widely used in the clinical management of colon and head and neck cancers. 5-
FU is structurally similar to uracil; however, a fluorine atom replaces a hydrogen 
atom at the C-5 position. After administration, 5-FU is transport into cells, where 
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it is converted into the powerful TS inhibitor fluorodeoxyuridine monophosphate 
(FdUMP). FdUMP has the same affinity to TS as dUMP: however, when bound to 
TS, the fluorine atom at the 5’ position cannot be displaced, and it forms a stable 
ternary complex with TS and 5,10-CH2THF resulting in TS inhibition. TS inhibitors 
based on folate analogs include tomudex (raltitrexed), liposomal GW1843U89, 
and capecitabine (Rose, Farrell et al. 2002). 
Expression of TS after exposure to anti- therapy, such as 5-FU has shown to 
increase proteins levels, a consequence of inhibiting TS activity, thus allowing 
translation of the mRNA and production of the protein(Van der Wilt, Pinedo et al. 
1992). 
Although 5-FU has been used for many decades in the clinical management of 
cancers, its use has been limited by drug induced toxicities and acquired 
resistance by cancer cells.  Cancer resistance to TS inhibitors can occur through 
a number of mechanisms.  TS can be over expressed in tumors due to gene 
amplification or mutations that may cause resistance. TS auto-regulates its gene 
expression, by binding to its mRNA. However, upon treatment with TS inhibitors, 
bounded TS is released from its mRNA allowing its translation, which in turn 
increases intracellular TS protein levels (Chu and Allegra 1996). The 
effectiveness of 5-FU depends on the availability of 5,10-CH2THF. The active 
metabolite, FdUMP forms an unstable binary complex with the enzyme, resulting 
in poor inhibition. However, in the presence of 5,10-CH2THF stabilizes the 
ternary complex inhibiting the catalytic function of the enzyme (Aherne, 
Hardcastle et al. 1996). Thus, tumors expressing low levels of 5,10-CH2THF are 
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resistant to 5-FU, however, addition of the drug Leucovorin (LV), increases 
intracellular levels of 5,10-CH2THF resulting in enhanced sensitivity (Matherly, 
Czajkowski et al. 1990). Another mechanism of resistance is the salvage 
pathway which allows for the recovery of free bases, such as thymidine that are 
byproducts of degrading DNA, to be recycled for nucleotide biosynthesis through 
the action of the enzyme, thymidine kinase (Kinsella, Smith et al. 1997). The 
salvage pathway can compensate for the lack of thymidylate production resulting 
from TS inhibition.  Acquired resistance cancan also result from mutations in 
TP53 wherein damaged DNA resulting from mis-incorporation of FdUTP is 
unrecognized allowing cells to escape apoptosis (Ahnen, Feigl et al. 1998). On 
the other hand, cancer cells with wild type TP53 can still be resistant to 5-FU 
therapy by altering the regulation of the cell cycle. In the presence of 5-FU  
resistant cells had increased tendency to arrest in G1 and G2 phases, allowing 
DNA repair prior to replication; unlike the parental cell line that had a tendency to 
arrest in the S phase (De Angelis, Svendsrud et al. 2006). In addition to acquired 
resistance, 5-FU therapy is limited by drug induced toxicities associated with its 
lack of specificity, targeting both actively dividing cancer as well as healthy 
normal cells. Some side effects from 5-FU include alopecia, myelosuppression, 
and mucositis. Considerable attempts have been made to enhance the 
effectiveness of 5-FU, while lowering its toxic side effects. These include the 
combination of 5-FU chemotherapy with targeted therapies. The impact of 5-FU 
on stromal cells is only beginning to be explored. Targeting both the tumor and 
tumor microenvironment might enhance our ability to kill colorectal cancer cells.  
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We hypothesize that stromal cells are also direct targets of 5-FU and that their 
chemo-sensitivity to 5-FU might determine tumor sensitivity to the therapy. 
Targeting the microenvironment is genetic modification or pharmacological 
inhibition of pro-tumorigenic activities of bone marrow derived cells infiltrating the 
tumor microenvironment, might be viable strategies to enhance anti-cancer the 
anticancer efficacy of 5-FU. 
 
1.6  PARADIGM SHIFT IN ANTI-CANCER THERAPIES 
 Targeting both the tumor as well as the tumor stroma is a paradigm shift in 
our approach to enhance the efficacy of anticancer therapies while enhancing 
selectivity and minimizing toxicity and relapse. Clinical trials targeting the 
extracellular matrix (ECM), endothelial cells and pericytes, fibroblasts, and innate 
immune cells have shown progress in combating cancer (Joyce 2005), however, 
these strategies are only beginning to be developed. The recognition of tumors 
as a complex collection of cancer cells interacting and recruiting normal non-
cancerous cells has altered our perception of cancer development, which has 
also alter  how we must combat this disease. Traditionally, anti-cancer therapies 
only targeted actively proliferating cancer cell by surgical removal of the tumor 
mass that may be combined with radiation or chemotherapy, or a combination of 
both. These treatments have only been moderately effective. Since the 
establishment of  the critical role of the tumor microenvironment in cancer 
initiation and progression, new anti-cancer therapies have emerged (Hanna, 
Quick et al. 2009) that can be harnessed to enhance the efficacy of prominent 
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existing chemotherapeutic drugs such as 5-FU. Furthermore, targeting stromal 
cells might provide an opportunity to enhance the specificity of cancer 
chemotherapies.  Thus, combining genetic modulation or pharmacologically 
inhibition of bone marrow derived cells (BMDCs) within the TME with 5-FU 
therapy may be beneficial in reducing drug toxicity or the occurrence of relapse.  
 
1.7 GENETIC MODULATION OF BONE MARROW DERIVED 
CELLS 
 The plasticity of BMDCs has the potential to constitute a pro-tumorigenic 
microenvironment for cancer cells. A review by Chantrain proposes three 
mechanisms by which bone marrow cells support the initiation and progression of 
cancer: first, through the recruitment of cancer cells to enrich the 
microenvironment, second, by infiltration into the tumor stoma to suppress 
immune response, and third, by promoting the development of the pre-metastatic 
niche (Chantrain, Feron et al. 2008). Numerous studies have demonstrated an 
array of pro-tumorigenic responses from BMDCs infiltrating the into primary 
tumor microenvironment permitting tumor growth (Egeblad, Ewald et al. 2008; 
Roorda, ter Elst et al. 2009; Fowler, Mundy et al. 2012; Kidd, Spaeth et al. 2012; 
Srivastava, Andersson et al. 2012; Zou, Zheng et al. 2012). Tumors have 
suppressed immune responses to recruit and activate MDSCs, which have been 
associated with malignancy and poor prognosis (Srivastava, Andersson et al. 
2012). In addition, BMDCs can influence the development of the vasculature of 
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the tumor tissue, hampering the administration and reducing the effects of 
anticancer drugs (Mizukami, Sasajima et al. 2012). The ability of BMDC to 
circumvent immune response and reduce efficacy of anti-neoplastic drugs is the 
subject of ongoing investigation. It is important to understand the role of BMDCs 
in tumor stoma to determine if genetic modulation of these cells can enhance 
efficacy of antitumor drugs. Transplantation of genetically modificed BMDCs may 
be used to alter gene expression in stromal cells to enhance tumor response to 
pre-existing therapies. For example, the knockdown of the Wnt signaling inhibitor 
Dickkopf1(DKK1) in bone marrow derive mesenchymal stem cells (MSCs) 
repressed myeloma development in mice (Fowler, Mundy et al. 2012), and  
MSCs engineered to express lymphotoxin induced tumor regression (Zou, Zheng 
et al. 2012).  Genetic modification of BMDCs might be an effective tool to 
enhance the efficacy of anti-neoplastic therapies since they can influence tumor 
resonse to therapy by their ability to suppress immune responses.  
1.8 PHARMACOLOGICAL INHIBITION OF BMDCs 
 An alternative to targeting the TME is by inhibiting the pro-tumorigenic 
activities of BMDCs, such as mast cells, pharmacologically. Mast cells have been 
shown to play critical roles in tumor initiation, progression, and response to 
therapy. Thus, effective anti-cancer therapies may need to target mast cells in 
addition to cancer cells. Several studies have used the pharmacological 
stabilizer, sodium cromoglicate (Cromolyn), a drug known to inhibit mast cell 
degranulation. Initially Cromolyn was used to treat acute inflammation which 
occurs during an asthma attack (Altounyan 1975). However, recent studies have 
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shown a reduction in tumor burden mice after administration of Cromolyn 
(Gounaris, Erdman et al. 2007; Soucek, Lawlor et al. 2007). Based on these 
results, we have considered the possibility that Cromolyn might play a synergistic 
role in anti-cancer therapy. However, the mechanism by which Cromolyn inhibits 
mast cells is not fully understood. It is thought to stiffen the cellular membrane, 
which indirectly inhibits the influx of chloride into the cell that in turn inhibits the 
ability of the cell ability to trigger. 
 
1.9 EXPERIMENTAL MODELS 
A. In-vitro cell model 
 Mus musculus thymidylate synthase (MusTS) was stably transfected into 
a TS-deficient Chinese hamster lung (CHL) cell line RJK88.13 (Nussbaum, 
Walmsley et al. 1985). Stable transfectants were selected in media lacking 
thymidine in the presence of the nucleoside transport inhibitor dipyridamole.  
Stably transfected cells were grown in mass culture.  The CHL(MusTS) cell line 
was used to target TS specifically to assess the sensitizing effects of diminished 
TS expression in response to 5-FU therapy.  
 
B. Transgenic mouse model 
 The C57BL/6J-ApcMin/+ mouse has been used as an in vivo model for the 
initiation and progression of intestinal adenomas. These mice are heterozygous 
for a mutant allele of the APC tumor suppressor gene, which genetically  
predisposes them to the spontaneous development of adenomas within the 
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intestinal tract (Moser, Pitot et al. 1990). Tumors develop in these mice at an 
early stage due to the loss of the remaining wild-type APC allele, which leads to 
insufficient expression of APC (Powell, Zilz et al. 1992; Su, Kinzler et al. 1992). 
The APC mutation is similar to that the germline mutation found in the human 
hereditary form of colorectal cancer, familial adenomatous polyposis (FAP) 
(Levy, Smith et al. 1994). Although FAP accounts for less than 2% of colorectal 
cancer incidence, mutations in the APC gene have accounted for 80% of 
sporadic colon tumors (Kinzler and Vogelstein 1996). Most of the adenomas that 
develop in these mice are located in the small intestines with a few developing in 
the colon, while in humans tumors develop exclusively in the colon.  
Nevertheless, the ApcMin/+mouse model is useful for understanding the initiation 
of tumor development and progression, and is a useful tool for developing or 
examining the effects of therapeutic agents in vivo. 
 
C. Syngeneic mouse model 
 The transplantable syngeneic CT26 tumor model in Balb/c mice is another 
model to examine the role of microenvironment in tumor response to 5-FU 
therapy. CT26 colon adenocarcinoma cells are injected into the flank of Balb/c 
mice where tumors are allowed to develop prior to therapy. CT26 cells were 
generated in Balb/c by treatment with the carcinogen N-nitroso-N-methylurethane-
(NNMU) where they were isolated and to grow in vitro (Brattain, Strobel-Stevens 
et al. 1980). The tumorigenic property of this cell line was sustained when 
transplanted into Balb/c mice, thus providing the ability to assess tumor growth 
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rates. By using this model, it allows for rapid tumor growth, which can be excised 
to quantify BMDC infiltration and expression of mRNA levels within the tumor. 
Thus, this syngeneic mouse model is practical for studying the response of 
BMDCs after exposure to different combinations of chemotherapeutic agents.  
 
1.10 REVIEW OF LITERATURE  (GENETIC MODULATION OF 
BMDCs) 
A. BMDCs infiltrate the intestinal tumor microenvironment in 
ApcMin/+mice.  
 In previous studies, Davis et al. showed that bone marrow can be 
successfully transplanted and engrafted into ApcMin/+ mice. Prior to 
transplantation, the recipient ApcMin/+ mice were lethally irradiated with 950 rads 
to deplete existing hematopoietic system.  Age matched donor marrow from 
C57BL/6-UB1-eGFP mice expressing the enhanced green fluorescent protein 
(eGFP) under the control of the human ubiquitin promoter was extracted from the 
femur and tibia. The bone marrow is directly transplanted into recipient mice, or 
grown in culture and fractionated to obtain hematopoietic stem cells (HSCs). 
Transplantation of whole marrow or purified HSCs was performed by tail vein 
injection. Full engraftment occurs within four to six weeks after transplantation. 
Tissue sections were collected at eight weeks post transplantation to examine 
the engraftment of donor eGFP bone marrow by confocal microscopy. The 
results showed that donor derived eGFP marrow infiltrated both normal and 
tumor regions of the small intestine and colon.  Infiltration of the eGFP bone 
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marrow was greater in tumor regions (75-80%) within the small intestines and 
colon as compared to normal, non-tumor regions (10%) (Davis, Price et al. 
2011). These results suggest that genetically modified bone marrow derived cells 
transplanted into ApcMin/+ mice will successfully infiltrate the tumor regions of the 
intestines and colon.   
 
B. BMDCs expressing E. coli TS exhibits resistance to TS inhibitors. 
 Previous studies have demonstrated that the an Escherichia coli TS gene 
whose codon usage has been optimized for expression in mammalian cells 
(OPTecTS) can confer high levels of resistance to TS inhibitors (Fantz, Shaw et 
al. 2000; Shaw, Berger et al. 2001). Shaw et al. optimized the E. coli TS gene by 
introducing mutations in the cDNA resulting in stabilization of the protein in 
mammalian cells. OPTecTS was cloned into a Harvey murine sarcoma-based 
retroviral vector and stably transfected into a TS-deficient CHL cell line  
(Nussbaum, Walmsley et al. 1985); wild type ecTS (wtecTS) and humanTS (hTS)  
were used as controls. Stably transfected cells expressing OPTecTS and the 
controls were treated with various concentrations of the TS inhibitor, raltitrexed 
(RTX) in the presence of dipyridamole to determine the concentration that 
inhibited the growth of fifty percent of the treated cells (IC50). The results showed 
that cells transfected with OPTecTs were 11-fold more resistant to RTX than 
cells expressing hTS while cells expressing wtecTS were slightly more resistant 
compared to cells expressing hTS. In addition, result showed greater than 75% 
and greater than 95% of bone marrow cells transduced with OPTecTS were 
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resistant to the TS inhibitors RTX and U89 respectively, at concentrations where 
100% of non-transduced cells were inhibited. 
 
C. The effects of chemo-resistant marrow on tumor response to TS 
Inhibitors. 
 In previous studies, chemo-resistant marrow expressing the OPTecTS 
was transplanted into ApcMin/+ mice. Retroviral vectors based on the murine stem 
cell virus (MSCV) promoter were constructed to express OPTecTS, while the 
MSCV empty vector was used as controls.  Lethally irradiated ApcMin/+mice were 
reconstituted with chemo-resistant (OPTecTS) or control BMDCs, and and then 
subjected to systemic treatment of a combination therapy of 5-FU and RTX or 
PBS as control treatment. After the treated mice were sacrificed, intestinal 
tissues were isolated and the tumor burden was determined. The results showed 
that in mice transplanted with mock transduced marrow, systemic treatment with 
5-FU caused a statistically significant decrease in tumor burden by approximately 
75% from 32±19 (PBS) to 8±5 (5-FU/RTX) (p=0.008). In contrast, in mice 
transplanted with drug resistant marrow expressing OPTecTS, tumors were not 
as responsive to the therapy exhibiting a statistically insignificant reduction in 
tumor burden from 35±22 (PBS) to 19±23 (5-FU/RTX) (p=0.183) (Pena et al, 
unpublished data). These results showed that genetically modified chemo-
resistant bone marrow does influence tumor response to chemotherapy. These 
preliminary data provides the basis for our working hypothesis that (1) tumor 
response to chemotherapy is influenced by the sensitivity of tumor associated 
  
24 
BMDCs and (2) it is possible that BMDCs can be genetically modified to chemo- 
sensitize both BMDCs and tumors to chemotherapy.  
 
1.11 REVIEW OF LITERATURE (INHIBITION OF BMDCs) 
A. Effect of systemic 5-FU therapy on tumor burden in ApcMin/+ 
mice 
 Tucker et. al. subjected ApcMin/+ mice to systemic treatment consisting of 
three cycles of 40 mg/kg 5-FU administered intraperitoneal (i.p.) daily for five 
consecutive days (Tucker, Davis et al. 2002).  Mice were either immediately 
sacrificed after the 5-FU regimen, or allowed to recover for 6-weeks post 
therapy. At the end of the treatment regimens, intestinal tissue was removed 
and tumor burden was assessed. The results showed that 5-FU reduced tumor 
numbers by approximately 50% (p<0.001) compared to age matched control 
groups treated with PBS.   In addition, weekly blood samples were collected to 
assess the effect of 5-FU on leukocytes. The results showed a reduction in 
leukocyte counts after exposure to 5-FU, and a return to normal or higher levels 
upon cessation of 5-FU therapy. When mice were allowed to recover for six 
weeks post therapy, there was no significant difference in tumor numbers 
between mice treated with PBS or 5-FU. This suggested that 5-FU therapy was 
only cytostatic to the tumor cells and after removal of therapy; the tumors 
relapsed to the same level as that in untreated mice. This study showed that 5-
FU can inhibit tumor growth, but it also showed that it can affect the leukocyte 
population in tumors and systemically in mice. The increase of leukocytes post 
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therapy, particularly in the tumor stroma may contribute to the growth of tumors 
post therapy. Thus, it is important to identify and further investigate the full 
impact of 5-FU not just on leukocytes but also on other BMDCs in the 
microenvironment such as mast cells, to determine their effect on tumor 
response to therapy and recurrence post therapy.  
B.  Examining the effects of 5-FU on mast cells and precursors 
 A previous study from our lab examines the effects of 5-FU on subsets of 
BMDCs, including mast cells, T regulatory (Treg) cells, and MDSCs in the tumor 
stroma in the ApcMin/+ mouse (Acharya, G., et.al, unpublished data). Briefly, 14-15 
week old mice were injected i.p. with a single dose of 50 mg/kg 5-FU. The mice 
sacrificed at 3,5,7,9 and 12 days post therapy.  Tumors, spleen, and bone 
marrow were collected, digested to create a single cell suspension and the 
infiltrating BMDCs were quantified by flow cytometry. The results showed that 
MDSCs were selectively sensitive to 5-FU while mast cells were resistant and 
migrated to the tumor stroma in response to 5-FU while the Tregs were only 
mildly sensitive to 5-FU. Analysis of apoptotic and proliferative indices of mast 
cells and MDSCs showed that in mast cells, these indices were unaffected by 
treatment with 5-FU. At 5 days post therapy, the number of mast cells infiltrating 
the tumor stroma increased; this was accompanied by a corresponding decrease 
in mast cell population in the spleen, suggesting that mast cells might migrate 
from the spleen to the tumor stroma in response to 5-FU and molecular signals 
from the residual tumor.  In contrast, MDSCs had a high proliferative index that 
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most likely rendered them vulnerable to 5-FU. The number of MDSCs decreases 
by three-fold within 5 days of 5-FU administration in tumor stroma, spleen, and 
bone marrow.  However, they returned to pre-treatment levels within 10 days.  
 In another study, the effect of 5-FU on mast cell precursors was 
determined in 8-week old C57BL/6 mice (Ophir, Berenshtein et al. 1993). Mice 
were injected intravenously once with 0–150 mg/kg 5-FU. BMDCs were collected 
at 2 and 4 days after injection and cultured in enriched media for 14 days to 
stimulate the proliferation of mast cell precursors. Toluidine and alcian blue 
staining identified mast cells. In response to 50 mg/kg the sub lethal dose of 150 
mg/kg 5-FU, BMDCs retrieved on day 2 after 5-FU injection yielded 12.2±0.9% 
and 2.6±0.3% mast cell precursors, while day 4 yielded greater than 80% and 
60% mast cell precursors, respectively. Normal levels of mast cells were 
observed by day 8 for the sub lethal dose. Data from the sub lethal dose 
indicated that mast precursors were continuously activated or cycling after 5-FU 
injection. Thus, there was gradual replacement, instead of recovery of mast cells 
in the bone marrow compartment. These preliminary data collectively provides 
evidence which support our working hypothesis that (1) tumor response to 
chemotherapy may be influenced by the sensitivity of tumor associated mast 
cells, and may interfere with tumor development, (2) effect of 5-FU on mast cells 
may play a synergistic role to enhance its anti-tumor efficacy, or (3) inhibition of 
mast cells may prolong  tumor recurrence. 
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1.12 RESEARCH GOAL 
 The preliminary data showed that tumor response to TS inhibitors was 
influenced by the sensitivity of tumor associated BMDCs to the therapy.  Genetic 
modification of BMDCs to make them resistant to TS inhibitors also made tumors 
resistant to the therapy.  The goal of this project is to develop a therapeutic 
strategy to target both cancer cells and non-cancer tumor stromal cells to 
enhance the efficacy of TS inhibitors. I will examine the ability of reducing 
intracellular TS levels by utilizing small RNA interference technologies against TS 
to enhance sensitivity to TS inhibitors. Genetically modified BMDCs that are 
sensitized to TS inhibitors are predicted to enhance the cytotoxic effects of 5-FU 
within the tumor upon infiltrating the TME while protecting normal non-cancerous 
cells from drug-induced toxicity.  
 In addition, I will test the hypothesis that pharmacological inhibition of 
mast cell activity will also inhibit their pro-tumorigenic role within the TME will act 
synergistically with 5-FU as well as prolong tumor relapse post therapy. My 
overall goal is to target the TME to enhance the cytotoxicity of 5-FU to cancer 
cells and to reduce tumor recurrence post therapy.  
 
1.13 RESEARCH INNOVATION 
 The realization that tumor stromal cells have profound influence on tumor 
behavior and tumor response to anti-neoplastic therapies is leading to a 
paradigm shift in cancer therapy. These findings suggest that effective therapies 
should also target these cells in addition to tumor cells.  I will explore the 
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possibility that altering the sensitivity of the cells in the microenvironment will also 
alter tumor response to therapy.  I will use the Osteopontin (OPN) promoter that 
is primarily upregulated and highly activated within tumor stromal cells to drive 
the expression of a TS shRNA sequence to sensitize the infiltrating BMDCs and 
the tumor prior to chemotherapy. The use of a promoter that is only activated in 
the tumor stroma, will not only enhance tumor sensitivity to the therapy but will 
also specifically direct tumor sensitivity to tumor cells while reducing toxicity to 
normal cells. This strategy to enhance the efficacy and the specificity of 
anticancer therapies can be applied not just too intestinal tumors but to other 
classes of therapeutic agents in different types of tumors. 
In addition, to modifying BMDCs I will use a drug known to specifically inhibit 
mast cell degranulation during and post post 5-FU therapy to determine if mast 
cells inhibition can synergize with 5-FU anticancer efficacy or prolong tumor 
recurrence of tumor after chemotherapy. The novelty of inhibiting mast cells is 
the utilization of the drug Cromolyn that has been used in treating asthma and is 
readily available on the market. Even though this drug has displayed success in 
reduction of various tumors, the combination of Cromolyn and 5-FU needs further 
investigation.  
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CHAPTER 2 
 
DEVELOPING STRATEGIES TO INCREASE CHEMO-SENSITIVITY OF 
CELLS TO THYMIDYLATE SYNTHASE INHIBITORS 1 
 
 
 
 
 
 
 
 
 
 
 
 
_______________________________ 
1 Developing Strategies to Increase Chemo-sensitivity of Cells to Thymidylate 
 Synthase Inhibitors, Nikeya L. Tisdale, Karen W. Barbour, Maria 
 Marjorette O. Peña. To be submitted.  
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2.1 ABSTRACT: 
 Thymidylate synthase (TS) is an essential enzyme necessary for DNA 
replication and repair; it is responsible for the synthesis of thymidine. Typically, 
cancer cells exponentially proliferate at higher rates, resulting in elevated TS 
activity. Thus, using TS inhibitors has been promising in treating cancer. 
Although, like any drug TS inhibitors do exhibit problematic pitfalls that include 
harming normal non-cancerous cells, the occurrence of cancer resistance and 
relapse to therapy. Attempting to circumvent these limitations, we used RNAi 
vectors to suppress cellular levels of TS. Reduction of TS expression did 
enhance sensitive to therapy, however the toxicity of the RNAi vector made it 
impossible to examine the effects in vivo.  
 
2.2 INTRODUCTION: 
 Thymidylate synthase (TS) is an enzyme that catalyzes the reductive 
methylation of dUMP to produce dTMP and dihydrofolate (Danenberg 1977; 
Carreras and Santi 1995). Subsequent, phosphorylation converts dTMP to dTTP, 
an essential precursor for DNA synthesis. This catalytic activity provides the sole 
intracellular de novo source of dTMP, thus TS is essential for actively dividing 
cells.  Due to this, TS is an optimal target for anti-cancer therapies(Wilson, 
Danenberg et al. 2014).Examples of TS inhibitors are 5-fluorodeoxyuridnine 
(FdUMP), Raltitrexed, and 5-Fluoruouracil (5-FU). 
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 The most commonly TS inhibit is 5-FU which has been used in the clinical 
management of many cancers. Inhibition occurs after 5-FU is transported into 
cells and converted into several metabolites. One metabolite is FdUMP, a 
powerful TS inhibitor. It disrupts DNA synthesis by forming a covalent ternary 
complex with TS and the substrate 5,10-methylenetetrahydrofolate. Inhibition 
results in the accumulation of dUMP, which is subsequently phosphorylated into 
dUTP. The incorporation of dUTP into DNA, triggers DNA fragmentation and 
ultimately cell death. Although, 5-FU is clinically used to treat cancer there are 
some drawbacks to this therapy, such as acquired resistance and the lack of 
specificity. Acquired resistance requires increase doses of 5-FU needed to kill 
cancer cells; however, the dose administered is limited by its lack of specificity 
resulting in toxicity to normal cells. 
In addition, to its catalytic function, TS negatively auto-regulates its 
intracellular protein level, by binding to its mRNA to block translation.  To mitigate 
the effects of 5-FU, TS protein bound to its mRNA are release to permit 
translation leading to induction of TS protein, exhaustion of 5-FU, lowering cell 
response and development of resistance to 5-FU. (Chu and Allegra 1996). 
Another, disadvantage of 5-FU therapy is its lack of specificity, targeting both 
actively dividing cancer and healthy non-cancerous cells. This leads to side 
effects such as alopecia, myelosuppression, and mucositis, due to sensitivity of 
non-cancerous cells in the hair follicles, the bone marrow compartment, and the 
intestinal lining which are always cycling and are vulnerable to 5-FU. Thus, there 
have been many attempts to enhance its efficacy while lowering toxic side by 
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developing new therapies or technologies to be used in conjunction with 5-FU 
(Natoli, Lupertz et al. 2013). 
 RNA interference (RNAi) is a novel technology that specifically lowers 
cellular expression of a target gene of interest. It involves using short interfering 
double stranded RNA (siRNA) or vectors driving the expression of short hairpin 
sequences (shRNA) that are complementary to a target mRNA sequence. 
Dependig on whether the siRNA is a perfect or imperfect match, binding to the 
mRNA can cause its degradation or inhibit its translation, both resulting in 
lowering the expression of the encoded protein (Hammond, Caudy et al. 2001; 
Ku and McManus 2008). This technology has been beneficial in regulating gene 
expression in cancers. A study targeting cyclin D1 with a silencing sequence 
resulted in sensitivity to 5-FU (Seo, Jeong et al. 2013). More specifically a 
number of studies have utilized RNAi against human thymidylate synthase in 
cells to show that depletion of TS mRNA and protein levels can circumvent the 
mechanism of resistance that occurs after exposure to TS inhibitors (Schmitz, 
Chen et al. 2004; Yang, Cloud et al. 2006).  
 Although the use of RNAi against TS results to sensitize cells to TS 
inhibitors is a promising strategy, these studies have only been performed in 
cancer cell lines; the efficacy of this strategy and tumor response to this therapy 
needs to be examined in mouse models in vivo. Targeting the TS siRNAs to cells 
in the tumor strom to sensitize tumors to the therapy has not been explored and 
provides a unique strategy to enhance antitumor efficacy. 
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 The goals in this chapter are 1) to identify siRNA sequences that can 
down regulated mouse TS expression in CHL (musTS) cell lines, 2) to determine 
if the siRNAs can sensitize cells to TS inhibitors. We sought to chemo-sensitized 
BMDCs to TS inhibitors by also using RNAi technologies against Mus musculus 
thymidylate synthase (Mus TS), to establish a chemo-sensitive TME within the 
ApcMin/+mouse model. Our results confirm that constitutive reduction of TS protein 
levels enhances 5-FU efficacy. Yet, our attempts to observed chemo-sensitive 
BMDCs response to therapy in ApcMin/+mice produced unfavorable results, 
demonstrates some negatives of using RNAi for therapeutic applications.   
 
2.3 MATERIAL AND METHODS: 
Mus musculus TS expressing vector 
 A 1 kilo-base cDNA corresponding to LUC3-7 Mus musculus TS mRNA 
was cloned into pBR322, a generous gift from Dr. Lee Johnson at Ohio State 
University (Perryman, Rossana et al. 1986). This plasmid was used as a 
template to PCR amplify mouse TS. The forward primer 5’ AAA AAA AGC TTT 
TTG TCG CTG ACT ACA CTG 3’  inserts a HindIII site at position -37 and the 
reverse primer 5’ TTT GTT AAC TTT TTT TTT TTA AAC AGC CAT TTC CAT 3’ 
inserts a HpaI site directly after a nine nucleotide poly A tail. The PCR amplified 
fragment was cloned into pSV2CAT with the HindIII/ HapI sites, removing CAT 
and replacing it with the 961 base pair amplified MusTS fragment. The resulting 
plasmid, PSV2CAT-MusTS was stably transfected into the TS deficient CHL cell 
line to generate the CHL (MusTS) cell lines expressing mouse TS. 
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Generating CHL (Mus TS) cell line 
Cell line RJK88.13, a TS deficient derivative of V79 Chinese hamster lung 
(CHL) cells, was a generous gift from Dr. Robert Nussbaum from the University 
of Pennsylvania(Nussbaum, Walmsley et al. 1985). Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Corning Cellgro, Manassas, VA) 
containing 4 g/L glucose, L-glutamine, sodium pyruvate, penicillin (100 U/mL), 
streptomycin (100 mg/ml), 10% heat inactivated fetal bovine serum (FBS) 
(Atlanta Biologicals Inc., Flowery Branch, GA) and supplemented with 10 uM 
thymidine at 37°C with 5% CO2 in a humified incubator. 
To generate CHL (MusTS) cell line the vector pSV2 (No CAT) expressing 
mouse TS, PSV2CAT-MusTS was stably transfected into CHL cell line with 
Liptofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Stable transfectants 
were selected in media lacking thymidine in the presence of 5 mM dipyridamole, 
a nucleoside transport inhibitor. Selected colonies were grown in mass culture.  
 
Characterization of siRNAs against mouse TS in cells  
 siRNAs against mouse TS were designed using software by Dharmacon 
RNA Technologies (Layette, CO) . The siRNAs were reconstituted in siRNA 
buffer (Dharmacon RNA Technologies) (100μM stock solutions). The sequences 
of two siRNAs against the Mus musculus TS mRNA sequence are: TS001 (GGA 
GCA GAG TAC AAA GAT A) and TS003 (GGG TAT AAT CCA CAT CCA A).  
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Twenty-four hours prior to siRNA transfection 1 ᵡ 106 cells were plated in 
duplicate in 2 ml of DMEM with 10% FBS in a 6 well plate.  Cells were 
transfected with either of the siRNA sequences using Dharmafect 1 transfection 
reagent following manufacturer’s instructions (Dharmacon RNA Technologies). 
Cells were collected post-siRNA exposure for immunoblot analysis. 
 
Sensitivity to siRNA transfected cells to 5-FU 
 5 -Fluorouracil was purchased from Sigma-Aldrich (St. Louis, MO). Stock 
solutions were made by dissolving in phosphate buffered saline (PBS) and filter 
sterilized using a 0.22 uM syringe filter.  Two treatments with siRNA were 
necessary to obtain sufficient down regulation of mTS during 5-FU treatment. 
The first exposure induced the reduction of mTS protein level, while the second 
exposure maintained the reduced protein levels for the duration of the treatment. 
To evaluate the cytotoxic effects of 5-FU in combination with siRNA treatment, 
0.5 x 105 CHL(MusTS) cells were plated in 1 mL DMEM with 10% FBS in 
triplicate in 6 wells pates. Twenty-four hours later cells were transfected with 2 
nM TS001 or scramble siRNA as control and allowed to incubate for forty-eight 
hours. After down regulation of TS, cells were treated with increasing 
concentration of 5-FU (0-1000 nM) and incubated for five days. Twenty-four 
hours after the addition of 5-FU, cells were subject to 4 nM or 10 nM siRNA or 
scramble siRNA. The second exposure ensured that TS was downregulated 
during the remainder of 5-FU treatment. An additional control were cells treated 
with 5-FU with no siRNA added. 
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 After 5 days, the cells were washed with Hanks buffered salt solution 
(HBSS), trypsinized, and counted in the presence of trypan blue to distinguish 
dead cells, using a hemocytometer.. The number of cells surviving at the end of 
the treatment were expressed as a percentage of the number of cells surviving in 
the absence of 5-FU. 
 
Construction of plasmid for constitutive down regulation of MusTS 
A double strand MusTS silencing oligo sequence was inserted into 
linearized pSuper RNAi vector to express short interfering RNA against MusTS 
(Oligo Engine, Seattle, WA). The silencing oligos contained the TS001 siRNA 
sequence (target sense sequence), but with the addition of a hairpin loop 
sequence TTC AAG AGA, the anti-sense sequence TAT CTT TGT ACT CTG 
CTC C, and the restriction sites Bglll or HindIII on the forward or reverse oligo 
respectively, resulting in two 60-nucleotide oligos (Integrated DNA Technologies, 
Coralville, IA).  The oligo strands were annealed together by mixing equal molar 
concentrations, heating at 90ºC for 4 minutes, followed by annealing at 70ºC for 
10 minutes, then gradually cooling to room temperature within 30-45 minutes.  
The annealed oligos were then cloned into the BglII and HindIII restriction sites in 
pSuper RNAi vector where their expression was under the control of the 
constitutive RNA Polymerase III H1 promoter. 
 The resulting vector plasmid, pSuper-MusTS001 (8-10 ug DNA) was 
transfected into CHL (MusTS) cells using Liptofectamine 2000 reagent. After 24-
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48 hours, cells were selected in 2 ug/mL puromycin (Invitrogen, Carlsbad, CA) to 
generate a stable cell line.   
 
Immunoblotting Assay and Quantification 
 Total protein extracts were obtained using M-PER protein lysis buffer 
(Thermo Fisher, Waltham, MA) following manufacturer’s instructions. Gel 
electrophoresis and membrane transfer were performed following standard 
procedures.  Membranes were incubated in rabbit polyclonal anti-mouse TS 
antibody (sc134130, Santa Cruz Biotechnology; 1:2000 dilutions in PBS-T/ 1% 
milk) overnight at 4ºC, washed with PBS-T, and incubated with horseradish 
peroxidase-conjugated anti-rabbit IgG antibody (BioRad; 1:1000 in PBS-T) for 1 
hour at 20°C. The same membrane was with mouse monoclonal anti-mouse 
actin antibody (β-actin-HRP ab49900,  Abcam,) (1:1000 in TBS-T/1% skim milk, 
1 h, 20°C). Bands were visualized using enhanced chemiluminescence plus 
(ECL Plus; GE Healthcare) and a Konica SRX-101A film processor. Band 
intensity was quantified using ImageJ software.   
Mice 
 Animal experiments were conducted in accordance with the guidelines 
and approval of the USC Institutional Animal Care and Use Committee. Mice 
were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and bred and 
maintained at the Mouse Experimentation Core Facility of the Center for Colon 
Cancer Research at the University of South Carolina (USC), Columbia, SC.  
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 C57BL/6-UB1-eGFP mice transgenically express the enhanced green 
fluorescent protein (eGFP), under the control of the human ubiquitin promoter. 
These mice were used as donors for bone marrow transplantation (BMT), to 
reconstitute lethally irradiated aged matched C57BL/6J-ApcMin/J mice (ApcMin/+). 
Bone Marrow Isolation  
 C57BL/6-UB1-eGFP donor mice were anesthetized by inhalation of 2% 
isoflurane in oxygen prior to sacrifice by cervical dislocation. Bone marrow (BM) 
cells were flushed from the femur and tibia using a 21-gauge needle into PBS 
containing 2% FBS. To quantify, red blood cells were lysed in ammonium 
chloride solution and mononucleated cells were counted using a hemocytometer.  
 
Transduction of CHL (Mus TS) cell line and Bone Marrow Derived Cells 
 CHL(Mus TS) cells were incubated in viral supernatant from GP+E86 
producer cells stably transfected with pSuper retroviral vectors expressing 
MusTS siRNA and scrambles siRNA containing 8ug/ml polybrene for 48 hours. 
Stable transductants were selected in 2ug/ml puromycin. 
  For bone marrow transduction, donor mice were injected i.p,with 150 
mg/kg 5-FU 48 hours prior to bone marrow isolation. Harvested marrow were 
cultured in DMEM 20% FBS, recombinant murine interleukin 3 ( IL-3, 20 ng/ml),  
recombinant murine interleukin 6 (IL-6, 20 ng/ml), and recombinant murine stem 
cell factor (SCF, 50 ng/ml) in suspension culture dishes (Corning Incorporation, 
Corning, NY) for 2 days. After 2 days, bone marrow cells were harvested and co-
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cultured with GP+E86 producer cells in the presence of 8ug/ml polybrene for an 
additional 2 days.  
 
Methylcellulose Assay 
 To evaluate chemo-sensitivity of transduced mononuclear cells. 
Approximately 15000 cells plated in 1ml of methylcellulose in the present of RTX 
(0-25nM) and 5µM dipyridamole. The number of progenitors was determined by 
counting colonies after 7 to 14 days.  
 
 
2.4 RESULTS: 
2.4.1 Identifying an effective siRNA target sequences against MusTS  
CHL(MusTS) were with two siRNAs TS001 or TS003, which were 
complementary to nucleotides 487-505 or 958-976, respectively. Cells with the 
siRNAs for 24-120 hours, their abilities to suppress TS expression were 
assessed. Western blot analysis showed a decrease in protein levels over time 
using both siRNAs (Figure 2.1a). Quantification of protein levels conveyed that 
TS001 and TS003 suppressed TS expression by 63% and 82%, respectively, 
within 24 hours, 14%, and 31%, respectively, by 48 hours (Figure 2.1b). Thus, 
TS001 was more effective at inhibiting protein expression and was used in 
further studies.  
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2.4.2 Enhancing sensitivity to 5-FU by using TS001 silencing sequence 
 To determine if downregulating TS expression with TS001 siRNA will 
sensitize cells to 5-FU, we treated cells with a second dose of TS001 siRNA 
ensure that TS expression was repressed for the duration of the experiment. 
Failure to maintain a sufficient level of siRNA made cells more resistant to 5-FU 
(data not shown). Cells were initially treated with 2 nM of the TS001 prior to 5-FU 
treatment. Twenty-four hours post 5-FU exposure, additional TS001 siRNA 
added to a final concentration of 4 or 10 nM were sufficient to maintain 
suppression of MusTS protein levels over the 5-day treatment (Figure 2.2a). The 
results from the growth inhibition curves also showed that cells treated with 
TS001 siRNA had lower IC50values. Cells exposed to either 4 nM or 10 nM final 
concentration of TS001 in combination with 5-FU had IC50 values of 1.00 nM or 
0.12 nM that were approximately 2.5- and 20- fold more sensitive, respectively, 
 
Figure 2.1: Down Regulation of MusTS with siRNA: a. Western blot analysis 
showing suppression of Mus TS protein in CHL (Mus TS) cells during a time course 
of 24-120 hours when exposed to 50nM of either TS001 or TS003 silencing 
sequences.  Actin was used as the loading control. b. Quantification of Mus TS 
protein represented in percentages after exposure to Mus TS silencing sequences 
at various times. 
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as compared to the control cells with an IC50 of 2.37 nM. Western blot analysis 
showed down regulation of MusTS protein levels only in cells treated with TS001 
siRNA (Figure 2.2b). Quantitation of the bands indicate that MusTS levels were 
 
 
Figure 2.2: Growth Inhibition Assay with siRNA: a. Growth inhibition curve 
displaying enhancement of sensitivity towards 5-FU in CHL (MUS TS) cells 
treated with various concentration of siRNA Mus TS sequence. IC50 values 
were 0.12nM, 1.00nM, and 2.37nM for cells treated with 10nM, 4nM, 0nM of 
TS001 siRNA respectively. b. Western blot analysis of Mus TS protein of cells 
in the absent of 5-FU and either treated with or without Mus TS silencing 
target sequence (TS001).  Cells treated with a final concentration of 10nM 
TS001 siRNA displayed the greatest reduction of Mus TS protein.  Actin was 
used as the loading control.  c. Quantification Mus TS protein after 5 days of 
transiently transfected with TS001 siRNA and exposure to 5-FU treatment.   
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reduced to approximately 93% and 85% in cells treated with 4nM or 10nM 
TS001, respectively, as compared to cells with no siRNA or those treated with 
scrambled siRNA (Figure 2.2c). These results showed that downregulation of 
intracellular TS levels can sensitize cells to 5-FU.  To translate these results in 
vivo, it is important to develop expression vectors that will maintain reduced 
MusTS levels in targeted cells constitutively as a mechanism to sensitize cells to 
TS inhibitors.  
 
2.4.3 Effects of constitutive expression of TS silencing sequence TS001 
To investigate the effects of continuous expression of TS001 we 
constructed pSuper retroviral vectors, which contains the RNA polymerase III 
promoter, H1 to drive shRNA expression.  The use of a retroviral vector, will 
allow expression of silencing MusTS shRNA constitutively to maintain sensitivity 
to TS inhibitos in vitro and in vivo without having to add additional siRNA.  
Transduction of CHL(MusTS) cells line or bone marrow derived cells with the 
retroviral vectors showed that constitutive expressesion of TS001 shRNA 
rendered cells more sensitive to 5-FU as compared to the cells transduced with 
control empty vector or scrambles shRNA (Figure 2.3a). We observed IC50 values 
of 33.07 nM, 2.69 nM, and 44.89 nM for cells expressing pSuper vector control, 
TS001 shRNA, or the scrambled shRNA, respectively. Thus, cells expressing 
TS001 shRNA were approximately 13-16-fold more sensitive to 5-FU as 
compared to cells expressing scrambled shRNA or empty vector.  Western blot 
analysis showed that MusTS levels were downregulated only in cells expressing 
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the TS001 shRNA retroviral vector (Figure 2.3a). MusTS levels in these cells 
were 40% less as compared to the control cells (Figure 2.3b).  This reduction of 
 
Figure 2.3: Growth Inhibition Assay with pSuper Constitutive Vector:   a. 
Growth inhibition curves of CHL (Mus TS) cells that were transduced with 
retroviruses to express the pSuper vectors or a silencing or a scramble 
sequence against Mus TS. All cells were exposed to increasing 
concentration of 5-FU to determine IC50 values. CHL (Mus TS) cells 
expressing the silencing sequence display more sensitivity to 5-FU. IC50 
values are 33.07nM, 2.69nM, 49.48nM for pSuper vector control, pSuper-
TS001, and pSuper-scramble respectively. b. Western blot analysis of CHL 
(Mus TS) transduced with pSuper retroviral vector expressing either TS001 
shRNA or the scramble sequences. Reduction of Mus TS protein is only 
observed in cells transduced with the silencing sequence. c. Quantification of 
the Mus TS protein shows the shRNA sequence reduces the expression of 
Mus TS protein by approximately 40%.  
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MusTS  protein confirmed that the shRNA retroviral vectors were functioning 
appropriately and that we have constructed an efficient shRNA vector against 
MusTS that is able to sensitized cells to 5-FU by suppressing protein levels. Next 
we transduced bone marrow cells to determine if these vectors can sensitize 
bone marrow cells to TS inhibitors. Transduced bone marrow progenitor cells 
where plated in methylcellulose in the presence of increasing concentrations (0 
nM-25 nM) of the TS inhibitor, raltitrexed. Approximately 50% growth reduction 
was observed in BMDCs that were constitutively expressing the MusTS shRNA 
in the presence of 5 nM RTX when only 88% or 75% growth reduction was 
observed in non-transduced or vector controls, respectively. In addition, colony 
growth at 10 nM RTX was observed in only the control groups but not in BM cells 
transduced with TS001 shRNA (Figure 2.4a), supporting the idea that the 
 
Figure 2.4: Examining Sensitivity of Transduce BMDCs expressing pSuper 
vectors: a. Colonies counts of bone marrow derived cells transduced to express the 
retroviral vector pSuper or pSuper-TS001 treated with increasing concentration of 
raltitrexed. Bone marrow expressing the Mus TS shRNA shows increase sensitivity to 
raltitrexed for exposure to 10nM concentration no colonies formed, however colonies 
developed in both the control groups.  b. PCR amplification of colonies that were in the 
absent of raltitrexed to confirm expression of retroviral vector pSuper of pSuper-TS001.  
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addition of an shRNA against MusTS is effective in sensitizing BMDCs to TS 
inhibitors. These results confirmed our ability to enhance the efficacy of TS 
inhibitors with the utilization of RNA interference technology. The question then is 
whether we can apply these strategies to sensitize the tumor microenvironment 
in vivo.  
To determine if the sensitization of bone marrow cells by TS001 shRNA in 
vitro can be recapitulated in mouse models in vivo, BMDCs transduced with 
pSUPER-TS001 shRNA were transplanted into lethally irradiated ApcMin/+ mice. 
However, reconstituting mice with BMDCs expressing either pSuper vector 
control or pSuper shRNA resulted in immediate death of the recipient mice. Since 
mice subjected to transduced bone marrow did not survive to engraftment, we 
 
Figure 2.5: Non-recovery of MusTS expression in BMDCs 
expressing pSuper vectors: Colonies counts of bone marrow 
derived cells transduced to express the retroviral vector pSuper or 
pSuper-TS001 in the present or absent of thymidine. The addition of 
thymidine does not recovery the colonies counts for bone marrow that 
expresses either pSuper or pSuper-TS001 vectors. 
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were unable to examine the effects of chemosensitive BMDCs in vivo. To 
determine if the constitutive down regulation of TS was the cause of the 
unsuccessful attempts to reconstitute irradiated mice, BMDCs transduced with 
the retroviral vectors were plated onto methycellulose in the presence or absence 
of thymidine and growth of progenitor cells were assessed and compared to non-
transduced cells. The results showed that the number of colonies did not differ 
significantly with the addition or lack of thymidine (Figure 2.5). Thus, the failure of 
thymidine to rescue transduced BMDCs from toxicity suggested that the retroviral 
vector pSuper was most likely problematic and toxic. To resolve this issue we 
used a different RNAi vector expressing system. 
 
2.5 DISCUSSION: 
 In this study, we investigated effect of diminished MusTS expression on 
the sensitivity of CHL (MusTS) or transduced bone marrow cells to TS inhibitors 
using siRNA technology. We identified an siRNA sequence that reduced 
translation of MusTS mRNA by approximately 37%.  Transfection of the siRNA or 
transduction of its corresponding shRNA in both CHL(MusTS) or bone marrow 
cells effectively sensitized cells to the TS inhibitor 5-FU. 
 Initially, to observed the response to therapy transiently transfecting cells 
with the2nM TS001 siRNA, displayed a resistance phenotype when expose to 5-
FU (data not shown). Plausibly reasoning for resistance is due to the delayed 
decrease in protein levels, due to using low concentration of the siRNA. 
However, resolving this problem by exposing the cells to higher concentration of 
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the siRNA could drastically affect proliferation and hamper cells response to 
therapy. Therefore, we decided to expose the cells to the low concentration of 
siRNA before therapy for the delay decrease in TS expression, providing 
sensitivity, and then gradually increase the concentration of the siRNA for the 
duration of the therapy to inhibit in additionally translation of the mRNA to reduce 
TS expression. Thus, to evaluate siRNA technology capability of sensitizing cells 
to TS inhibitors, it was necessary to establish slight reduction of protein level 
before therapy followed by a prolonged disruption in the ability to translate the 
mRNA, for the duration of the therapy. Indeed, we found that transfecting cells 
with a low concentration of the siRNA prior to 5-FU exposure induce sensitivity. 
However, to accomplish long-term reduction of protein expression, the addition of 
more siRNA was needed twenty-four hours after 5-FU treatment, resulting in a 
final concentration of   either 4nM or 10nM of the siRNA, which ensuring prolong 
down regulation of the protein, resulting in enhanced sensitivity towards 5-FU. 
Our results show an equivalence of either a 2 or20- fold increase in chemo-
sensitivity, of cells transiently transfected with either 4nM or 10nM TS001 siRNA 
respectively in the present of 5-FU.From these results, we established that 
siRNA technology is able to sensitized cells to chemotherapy. Nevertheless, is 
problematic and is not conductive for in vivo studies. The problem of providing 
efficient and permanent reduction of Mus TS gene expression was resolved only 
by the addition of more siRNA, yet this is a solution for in vitro studies is not 
conceivable in the attempt to sensitizing the TME in the  ApcMin/+mouse model. 
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 Therefore, it is necessary to use an RNA interference system that is vector 
base, and which we utilized the H1 promoter in the pSuper retroviral vector to 
drive the expression of the Mus TS shRNA to provide a permanent reduction in 
the Mus TS gene expression. The utilization of this retroviral vector allowed us 
the ability transduced CHL (Mus TS) and mouse bone marrow derived cells to 
express the shRNA against TS, such to develop and enhance sensitivity to TS 
inhibitors. Promising result from CHL (Mus TS) cells expressing Mus 
TSshRNAdisplayed13-fold increase in chemo-sensitivity towards 5-FU. We 
observed approximately a 40% reduction of protein expression, which is strikingly 
greater than the protein reduction observed from siRNA technology. Although, 
promising this 40% reduction in protein expression that occurred in CHL (Mus 
TS) cells, may translate into proliferation problems when expressed by BMDCs. 
For the delivery of Mus TS shRNA sequence within the TME of ApcMin/+ mice is 
contingent on the ability of bone marrow derived cells to proliferate, imperative 
for infiltration into the TME. 
 To assess this issue, retroviral particles were used to transduce bone 
marrow derived cells to examine the effects of stably incorporating the pSuper 
vector into the genome of these. The genetic modulate bone marrow derived 
cells expressing the Mus TS shRNA was used for both concurrent ex vivo and in 
vivo chemo-sensitive studies, for both studies required time for either colony 
formation or reconstitution engraftment of ApcMin/+mice that were subjected to 
irradiation to completely deplete existent bone marrow. Our ex vivo results of 
transducing mouse bone marrow derive cells to express the MusTS shRNA 
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sequence showed promising effects, of chemo-sensitivity toward raltitirexed. 
However, the occurrence of fatalities in ApcMin/+mice reconstituted with bone 
marrow expressing Mus TS shRNA seems to hinder cells ability to proliferate, 
due to cytotoxic effects. The data in which we attempt to recover cellular 
thymidine level with the addition of exogenous thymidine in BMDCs implicates 
that the pSuper vector is indeed toxic. The inability to recover colony formation in 
either vector control or shRNA expressing BMDCs proves that the pSuper vector 
system is problematic.  
Additionally, this in vivo result suggests that down regulation of Mus TS 
gene expression needs to regulate. TS is an essential enzyme for cell 
proliferation and to continuously suppress it’s expression is sure to have 
devastating outcomes, thus, in the future we intend to use an inducible promoter, 
one that activates only in the tumor microenvironment. In hopes to alleviate, any 
problem caused by the constitutive down regulation of Mus TS.  
 Overall our data suggest that the down regulation of MusTS expression 
prior exposure to chemotherapy is beneficial in reducing the concentration of 5-
FU required to inhibit cellular proliferation. These results are the effect of the 
mechanistic degradation or inhibition of translating of Mus TS mRNA that is 
target by RNA interference technology. The process of subjecting cells first to 
target Mus TS RNA interference disrupts cellular translation of the TS protein. 
The reduction in cellular protein levels is advantageous for requirements of 
inhibiting the catalytic activity of the protein have lessened. In addition the 
additive effect of utilizing RNA interference in combination with TS inhibitors 
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eliminates the induce activation of protein production, for MusTS mRNA is 
targeted for degradation prohibiting translation. 
 Clearly, many problems can occur with utilizing RNA interference 
technologies. However, used appropriately it may be beneficial in a variety of 
clinical disease processes.  
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CHAPTER 3 
  
CHARACTERIZATION OF THE ABILITY OF THE MURINE 
OSTEOPONTIN PROMOTER TO DRIVE THE GENE EXPRESSION 
SPECIFICALLY IN BONE MARROW DERIVED CELLS IN THE TUMOR 
MICROENVIRONMENT2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________ 
2Characterization of the Ability of the Murine Osteopontin promoter to Drive  
Gene Expression Specifically in Bone Marrow Derived Cells in the Tumor  
Microenvironment, Nikeya L. Tisdale, Sapana N. Shah, Celestia Davis,  
Maria Marjorette O. Peña. To be submitted.   
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3.1 ABSTRACT: 
 Osteopontin (OPN) has been implicated as a cytokine that plays an 
important role in cancer progression. It is secreted by a number of cells and jas 
been shoen to activate the function of many immune cells. Studies investigating 
the activity of the osteopontin promoter showed that it contains many enhancer 
sites, which are influenced by inflammatory stimuli. Here, we show that the 
regions encompassing (-777/-740 to +79) of the OPN promoter is responsive to 
inflammatory stimuli and can specifically be activated only in the tumor 
microenvironment of APCMin/+ mice. In addition, we have validated that the OPN 
promoter has the capacity to drive the expression of an RNAi sequence. The 
results of these studies indicate that the OPN promoter may be useful in directing 
the expression of chemo-sensitizing genes specifically in stromal cells in the 
tumor microenvironment. These will be useful in testing our central hypothesis 
that by sensitizing tumor stromal cells, it is possible to sensitize cancer cells to 
the therapy. 
 
 
3.2 INTRODUCTION:  
Endogenous gene silencing is mediate by microRNA (miRNA). The 
development and maturation of miRNA begins in the nucleus, where miRNAs 
are transcribe as part of long primary transcripts (pri-miRNAs), which contain 
multiple embedded hairpins. Drosha/Pasha, RNASE III enzymes cleaves these 
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pri-miRNAs into individual stem loops within the nucleus. These individual stem 
loops are precursor miRNAs (pre-miRNAs), which are approximately 70nt length 
double strand sequences (Yeom, Lee et al. 2006).  Pre-miRNAs are exported 
out of the nucleus by the protein Exportin 5 into the cytoplasm, to further, 
undergo processing by RNASE III enzymes, Dicer and RNA-induced silencing 
complex RISC to obtain gene silencing (Ku and McManus 2008). Dicer removes 
the stem loop structure to produce a ̴ 21-23nt long double stranded sequence, 
which is then subsequently incorporated into the RNA-induced silencing 
complex (RISC)(Hammond, Caudy et al. 2001). The RISC uses one strand of 
the double strand RNA as a guide to target the mRNA of interest for degradation 
or inhibition of translation, thus resulting in lowering expression of the encoded 
protein (Ku and McManus 2008). This mechanism of gene silence provides the 
template for exogenous mediated gene silencing accomplished by small 
interfering (siRNAs) or short hairpin RNAs (shRNAs). 
The widely utilized commercial synthetic siRNAs are ideal to examine the 
functional roles of genes in upstream and downstream processes during 
disease development. Upon entry into the cytoplasm of cells, the cytoplasmic 
enzymes of miRNA machinery process siRNAs to achieve inactivation of genes.  
Even though it has been advantageous, the utilization of siRNAs has limitations 
that include the inability to enter slowly dividing cells and the inability to sustain 
continuous suppression of gene expression. To circumvent these issues the 
development of shRNA viral expression vectors are modeled after pre-miRNAs. 
Typically, to provide constitutive repression of a gene, shRNA viral vectors 
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employed RNA polymerase (pol) lll promoters, H1 or U6 to control the 
expression of the shRNA sequence(Paddison, Caudy et al. 2002; Rossi 2008) . 
However, these vectors can be problematic, causing RNAi toxicity and they lack 
the capacity to be tissue specific (Boudreau, Martins et al. 2009) as previously 
discussed in Chapter2.  
Thus, modifications to shRNA expression vectors were developed to be 
more similar to pri-miRNA, by embedding the shRNA sequence into an 
endogenous miRNA backbone (shRNA-miRs), such as miR30 (Matveeva, 
Nazipova et al. 2012; Fellmann, Hoffmann et al. 2013). The advantage of this 
feature is that it enables the expression of the shRNA to be controlled by a RNA 
Polymerase II promoter. Additionally, this model system exploits the entire 
miRNA processing machinery resembling the natural maturation of gene 
silencing within a cell. This particular system eliminates the need to use a pol III 
promoter to drive the expression of a silencing sequence. Thus, we decided to 
use this model system to circumvent the problems that occurred when utilizing 
the constitutive retroviral vector pSuper, which uses the H1 promoter to drive the 
expression of the silencing sequence. We show that using the murine 
cytomegalovirus promoter (mCMV) a polymerase II promoter driving the 
expression of TS silencing sequence is an ideal expression system that will 
allow  us to examine the systemic effects of reducing TS expression in mice. 
The processes of gene expression is regulated by several influential 
factors such as frequency of transcription of a gene, post-transcription 
modification of messenger RNA, translation, and maturation or degradation of 
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protein. These regulatory processes enforce the balance of gene expression, 
which controls cellular function or development. Regulation of gene expression 
can be tissue specific, which is typical during developmental progression and the 
processes of wound healing or cancer. Reproducing and using the regulatory 
features of tissue specific gene expression can be beneficial for targeting 
therapies, hence alluding to the capacity to target only the tumor and its 
microenvironment.  
In devising the approach for specific targeting, it was essential to identify a 
gene that is only activate and expressed in the TME; and then use this gene’s 
promoter to drive the expression of an RNAi sequence against thymidylate 
synthase. We identified Osteopontin (OPN) as a potential candidate, since 
studies have shown that it plays a vital role in the progression of cancer, and is 
highly expressed in several tumors.  
The emerging evidence pertaining to OPN involvements in cancer 
development has led to its consideration as a biomarker (Cao, Li et al. 2012). 
OPN is a secretory extra cellular matrix (ECM) protein that is secrete by a variety 
of cells such as endothelial, epithelial, and activated immune cells.  Results have 
implicated the involvement of OPN in the interactions that occur between cancer 
cells and its tumor stroma (Gotoh, Sakamoto et al. 2002). OPN is highly 
expressed in a variety of human cancers. In particular, in  human gastric cancer 
OPN has been shown to be highly expressed in gastric cancer lesions, mildly 
expressed in the tumor stroma, and is negatively expressed in the normal 
regions of tissue sections(Ue, Yokozaki et al. 1998; Junnila, Kokkola et al. 2010). 
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In addition, a study comparing the alteration of gene expression in normal versus 
tumor intestinal tissues  revealed elevated levels of OPN in the polyps of APCMin/+ 
mice (Chen, Hao et al. 2004).  
Moreover, several studies have indicated that pro-inflammatory stimuli 
induce the transcription of OPN gene (Guo, Cai et al. 2001; Denhardt, Mistretta 
et al. 2003; Zhu, Denhardt et al. 2005). Guoet.al. demonstrated that the OPN 
promoter activity increased in the presence of lipopolysaccharide (LPS) and nitric 
oxide (NO). Furthermore, examination of OPN promoter identified several 
regions as pro-inflammatory response elements such as ras- activated 
enhancers that promoted the transcription of the gene in metastatic transformed 
cells or in cells exposed to hypoxic conditions(Guo, Zhang et al. 1995; Zhu, 
Denhardt et al. 2005).  In addition, identification of positive and negative 
regulatory cis- acting elements in various regions of the OPN promoter influences 
tissue specific expression (Higashibata, Sakuma et al. 2004). The premises of 
these studies indicate that the OPN promoter is an ideal candidate to use to 
target specifically the TME. 
Once, again all roads leads back to the TME stressing the importance of 
infiltration of BMDCs and their function in tumor progression and resistance to 
various chemotherapies. Important players in tumor progression that also, exhibit 
immune suppressive activities include mast cells; myeloid-derived suppressor 
cells (MDSCs) and regulator T cell (Tregs). Mast cells are effectors cells that 
release an array of pro-inflammatory mediators, which have shown to influence 
the migration and function of many hematopoietic derived cells in cancer 
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progression (Ribatti 2015). Crosstalk between mast cells and MDSCs was 
observed in a CT26 cancer model and was shown to  enhance the suppressive 
activities of MDSCs (Danelli, Frossi et al. 2015). MDSCs are a heterogeneous 
population of immature myeloid cells that are activated by the pro-inflammatory 
stimuli produced within the tumor or by mast cells. Activation of these cells 
results in suppression of T cell activation, which is necessary for antitumor 
immunity, permitting the immune system to be acceptance to tumor progression 
(Marvel and Gabrilovich 2015; Parker, Beury et al. 2015). MDSCs production of 
interleukin 17 (IL-17) have been shown to reinforce it suppressor functions by 
indirectly attracting regulatory T cells into the tumor (Yang, Zhang et al. 2010).In 
the presence of 5-FU, depletion of MDSCs have shown to result in two 
outcomes. First, the beneficial outcome results in the enhancement of T cell 
dependent antitumor activity (Vincent, Mignot et al. 2010). The other outcome 
supports tumor growth due to the secretion IL-1B by MDSCs, which recruits 
Tregs to produce IL-17 to assist with angiogenesis (Bruchard, Mignot et al. 
2013). The effect of 5-FU on tumor infiltrate mast cells response has not been 
elucidate, however reduction in mast cell progenitors followed by a rapid 
recovery was observed in the bone marrow and spleen of mice (Hokari, Tsuboi et 
al. 2011).  These studies highlight the importance for why chemotherapy 
sensitivity needs to be established in these particular BMDCs populations. 
Hence, reprogramming of these cells to be genetically more sensitive to therapy 
may be beneficial to how these BMDCs respond to therapy.  
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Thus, we sought to determine if utilizing the inducible characteristic of the 
OPN promoter could drive the expression of an RNAi sequence against Mus TS 
specifically within the tumor microenvironment to establish chemo –sensitivity of 
these cells to TS inhibitor. To accomplish this we demonstrated the OPN 
promoter (-740/ -777 to +79) regions are responsive to pro-inflammatory stimuli 
and are capable of driving the expression of mCherry a fluorescent protein only 
within the tumor microenvironment of APCMin/+mice. In addition, we validate that 
the -740 to +79 OPN promoter region is capable of driving the expressing of 
RNAi sequence against MusTS to enhance cellular sensitivity to 5-FU. The 
premises of our studies show that the OPN promoter can indeed provide specific 
chemo-sensitivity in the TME.  
 
3.3 MATERIAL AND METHODS:  
Lentiviral vector 
 We obtain the pZip lentiviral vector from Transomic Technologies. Dr. 
Greg Hannon and colleagues from Cold spring Harbor Laboratory developed this 
system, which is comprised, of an ultramiR scaffold shRNA, fluorescent marker 
Zsgreen, and the selectable marker puromycin constitutively driven by the 
mCMV promoter to establish efficient repression of a target gene. The MusTS 
shRNA sequence expressed by this vector is the following: 
TGCTGTTGACAGTGAGCGACAAGACCTTTCCCAAAGCTCATAGTGAAGCCA
CAGATGTATGAGCTTTGGGAAAGGTCTTGGTGCCTACTGCCTCGGA.  The 
lentiviral vectors were stably transfected into CHL (MusTS) cells following 
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manufacturer’s instructions. Selection of stable transfectants was done by 
incubating transfected cells with puromycin antibiotics and visual verification of 
Zsgreen expression in cells fluorescence microscopy and flow cytometry. 
 
Vector Construction 
 Vector pXP1-OPN (-777 to +79) was a generous gift from Dr. David T. 
Denhardt from Rutgers University. Regions -777 to +79 and -749 t0 +79 were 
PCR amplified using the forward primers: GGT ACC ATG CAT CTG CTC CAA 
CAG AGC AAC AAG GTT C or GGT ACC ATG CAT TCT CTA AAG GTC AGT 
GGA GGC AGG,  respectively, and the reverse primer: AAG CTT GAT ATC ACC 
GGT CTT GGC TGG TTT CCT CCG AGA ATG. Amplified regions were cloned 
into the retroviral vector pMSCV that contained the mCherry fluorescent protein. 
These retroviral vectors were transfected into viral producer cell line GP+E86.  
 The pZip lentiviral vectors were used to construct lentiviral vectors 
containing the OPN promoter. The MSCV promoter was replace with the OPN 
promoter by recombination cloning following manufacturer’s protocol for 
(Clonetech Infusion Cloning kit). Manufactures protocol for transfection was use 
to establish stable expression of the vectors in CHL (MusTS) cell line (Transomic 
Technologies). Confirmation of stable expression was acquired by exposing 
transfected cells to puromycin antibiotics and visual verification of Zsgreen 
expression in cells. 
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Transducing bone marrow derived cells 
 Dr. Boris Kantor of the Vector Core at the University of South Carolina 
produced the viral particles for the lentiviral vectors in the pZip backbone. . These 
viral particles were used to transduce bone marrow for reconstitution of lethally 
irradiated mice. 
 
Lethal irradiation and reconstitution of ApcMin/+or Balb/c mice 
 Four-week-old recipient ApcMin/+ mice were lethally irradiated utilizing the 
JL Shepard Cesium-137 irradiator by administering 190 rads/min for a total of  
950rads. 2–3 × 106 genetically modified mono-nucleated cells were transplanted 
into the lethally irradiated mice by tail vein injection within eight-hours of 
irradiation. Transplanted mice were administered sterile water containing 0.004% 
Baytril antibiotic (Bayer Animal Health Division, Shawnee, KS) for two weeks 
post-transplantation to prevent infection. These mice were used to determine if 
the OPN promoter is only activated within the intestinal tumor regions of a mouse 
model. Confirmation of successfully engraftment of genetically modified BMDCs 
was obtained 6 to 8 weeks post transplantation by bleeding mice and isolating 
genomic DNA from leukocytes. Genomic DNA was PCR amplified with primers to 
confirm incorporations of the mCherry gene.  
 Reconstituted 15-week old ApcMin/+ mice were humanely sacrificed by 
cervical dislocation. Their intestines were isolated, flushed with 1xPBS and cut 
open longitudinally. The tissues were fixed in 4% paraformaldehyde overnight. 
The fixed intestines were then swiss-rolled and embedded in paraffin cassettes 
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and left to dry overnight. 3-5 micron sections were mounted on standard 
microscopy slides and nuclei were stained with Dapi. 
 Four-week-old recipient Balb/c mice were lethally irradiated using the JL 
Shepard Cesium-137 irradiator by administering 950 rad at 190 rads/min. 
Transplantation and verification of engraftment of genetically modified marrow 
was performed as described above. 
 
Flow Cytometry  
 BMDCs were isolated from the femur, tibia, and blood from recipient mice. 
The single suspensions were incubated in ammonium chloride lysis buffer (150 
mM NH4Cl, 10 mM Na2CO3, 0.1 mM EDTA, pH 7.4) for 5 minutes on ice, in the 
dark to lyse the red blood cells, followed by centrifugation at 2000 rpm for 5 
minutes at room temperature and the supernatant discarded. Excess lysis buffer 
was removed by washing the pellet twice with cold PBS containing 2% FBS and 
then centrifuged at 2000 rpm for 5 minutes.  The cells were counted using a 
hemocytometer, and approximately 2 million cells were stained with antibodies 
against the cell surface markers CD45 for leukocytes, CD8a and CD8a for T 
cytotoxic cells, CD34 and CD117 for mast cells, CD4 and Foxp3 for T regulatory 
cells, and GR1 and CD11b for MDSCs for 1 hour at 4°C. To determine apoptosis 
index antibodies against Annexin V and Viability Dye eFluro 780 were used to 
stained particular cell populations. Antibodies against Ki67 determined the 
proliferation index for the different cell population. All antibodies for flow analysis 
obtained from Ebioscience. Excess antibodies were removed by washing cells 
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once with cold PBS containing 2% FBS and then centrifuged at 2000 rpm for 5 
minutes. The cell pellet was then resuspended in 500µL of PBS containing 2% 
FBS for flow cytometry analysis using a Beckman Coulter FC-500 flow 
cytometer.  
 
Immunofluorescence 
 The sections were deparaffinized, rehydrated, and  then incubated in a 
microwave oven  at 95oC with 0.01 M citrate buffer, pH 6.0 (Diagnostic 
Biosystems, Pleasanton, CA) for 10 minutes for antigen retrieval. Sections were 
blocked with 5% BSA for one hour. To identify apoptotic cells, the samples were 
incubated for 2 hours at 37oC. with a mixture of primary antibodies against 
cleaved PARP-1 (Rabbit polyclonal, 1:200 dilution, Santa Cruz Biotechnology, 
Santa Cruz, CA USA) and a cell-type specific cell surface marker such as CD11b 
for monocytes, Ly-6 for granulocytes, or c-kit  for mast cells (all the antibodies 
are rat monoclonal used at 1:200 dilution, all from Abcam, Cambridge, MA) in 1% 
BSA in PBS.  Samples were wash twice 1XPBS and stained with respective 
secondary antibodies conjugated to Cy-3 (surface markers) or Cy-5 (Parp-1) for1 
hour at 37oC. The sections were again washed with 1XPBS and then stained 
with DAPI. Stained sections were treated with ProLong Gold anti-fade reagent 
(Invitrogen, Frederick, MD) prior to applying the cover slips. 
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Confocal Microscopy 
 The slides containing sections stained with the various combinations of 
primary antibodies were imaged using Zeiss LSM Meta 510 confocal microscope. 
For each antibody combination, approximately 100 field view images were 
captured at 40 X magnification.   For each field view image, cells that stained 
positive for the specific cell surface markers were counted and scored as 
apoptotic if they also stained positive for cleaved PARP-1. Apoptotic indices were 
calculated as the percentage of cells that stained for both the cell surface marker 
and cleaved PARP against the total number of cells that stained positively for the 
specific cell surface marker. 
 
3.4 RESULTS: 
3.4.1 Examining the capacity of mCMV promoter to drive the expression of 
an RNAi sequence against TS in vitro and in vivo 
 To determine if the murine polymerase II promoter is able to drive the 
expression of an RNAi sequence against MusTS, we stably transfected the 
pZiplenti-viral vectors into the CHL(Mus TS) cell line to observe suppression of 
TS protein levels. Cells that were stably transfected with the pZip-mCMV-TS 
shRNA vector displayed a 67% expression of the protein and a 0.43 fold 
reduction in TS mRNA levels in these cells (Figure 3.1) when compared to the 
non-transfected cells. In addition, we observed a slight reduction of protein and 
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mRNA expression in the vector control cells, which was of concern due to the 
possibility that the vector might also prove to be toxic to transduced cells in an in 
vivo model. Thus, we determined the effect of expressing the lentiviral vectors on 
the growth rate of transduced cells as compared to control cells and non-
transduced cells. Twenty thousand cells were plated and the growth rate was 
monitored over 6 days. The results showed that there were no differences in the 
growth rates between these cells (Figure 3.1) providing assurance that the lentil-
viral vector system did not impair cellular proliferation and, thus may not be 
detrimental in an in vivo model system. To determine of the 33% reduction in 
MusTS level was sufficient to sensitize cells to 5-FU, we performed a growth 
inhibition assay.  The results showed that there was no increase in the sensitivity 
to 5-FU of cells that expressed the RNAi sequence against MusTS as compared 
to control cells expressing the empty vector (Figure 3.1). Despite its inability to 
enhance sensitivity, most importantly, it was necessary for us to determine if this 
vector system can be used to modulate BMDCs for successfully engraftment into 
tumor-bearing mice.  
 To examine the effects of transplanting BMDCs transduced with the 
pZiplenti-viral vectors in vivo, BMDCs were isolated from donor Balb/c mice and 
transduced with viral particles from either the pZip-mCMV control vector or pZip-
mCMV-TS shRNA vector using a multiplicity of infection of five. This resulted in 
approximately 20% of the BMDCs population expressing either vector as 
confirmed by fluorescence activated cell sorting (FACS) analysis to detect 
Zsgreen protein expression. This fluorescent marker in the pZip vector backbone 
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was used to confirm incorporation of vector into the cell’s genomic DNA and its 
expression within transduced cells. We used the bone marrow that was 20% 
Zsgreen (ie, transduced) to transplant and engraft into lethally irradiated Balb/c 
mice. The controls for this study were Balb/c mice reconstituted with BMDCs that 
expressed the vector control that contain the Zsgreen gene under the control of 
the mCMV promoter or GFP expressing transgenic BMDCs. 
 Four weeks post transplantation, genomic DNA from mice reconstituted 
with genetically modified bone marrow was extracted from the blood to confirm 
incorporation of the Zsgreen gene and the Ultramir 3’ and 5’ regions with the 
RNAi control or RNAi Mus TS sequence in the genome (Figure 3.2). This result is 
significant for since have identified an RNAi system that is safe to use in mice. 
Thus, by using the pZip-mCMV vector we confirmed that an polymerase ii 
promoter can drive the expression of an RNAi sequence against MusTS, and this 
RNAi vector system can be used to modulate BMDCs to successfully engraft in 
mice without exhibiting cytotoxic effects. These results suggest that we 
potentially have capability to direct tumor stromal specific sensitivity to 
chemotherapy drugs in an in vivo model. The potential to establish specific 
sensitivity is dependent on the ability of the promoter to drive the expression of 
the RNAi sequence. We identified the OPN promoter as a possible candidate. 
However, further examination of the promoter is necessary before the 
implementation of this RNAi vector system into in vivo mouse model of cancer. 
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c. e.d.
Figure 3.1: Examining the ability of mCMV Promoter to control an RNAi sequence. a. Depiction of the lenti-viral 
pZip-mCMV vector map.  b. Western blot analysis of CHL (Mus TS) stably transfected with pZip lenti- viral vector 
containing the mCMV promoter to drive the expressing both shRNA sequence and Zsgreen or the vector control which 
only drive the expression of the Zsgreen protein. Reduction of Mus TS protein is only observed in cells transduced with 
the silencing sequence. c. Quantification of the Mus TS mRNA shows the shRNA sequence reduces the expression of 
Mus TS protein by approximately 33%. d. Growth curve graph indicating that the growth rate of cells expressing the 
shRNA sequence is comparable to control cells or the cells expressing the vector control. e. Growth inhibition assay 
show that pZip vectors exhibit sensitivity to 5-FU therapy. 
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3.4.2 Characterizing the specificity and induciblity of the OPN promoter 
regions (-777/-740 to +79) 
 To determine responsiveness to inflammatory stimuli of the OPN promoter 
(-777/-740 to + 79) driving the expression of the gene encoding the mCherry 
fluorescent gene, cells transfecyed with these constructs were treated with 
different inflammatory stimuli. We exmined the expression of the mCherry reprted 
gene by microscopy and by immunoblot analysis of mCherry protein levels to   
 
 
 
assess the activation of the OPN promoter. Activation of the OPN promoter was 
accomplished by exposing cells to the systemic inflammatory stimuli LPS, the 
inflammatory cytokines interferon gamma (INF-γ) and interleukin 1-β (IL-1β), or 
condition media from cancer cell line CT26 that are thought to secrete molecules 
 
Figure 3.2: Confirming incorporation of pZip-mCMV lenti-viral vectors in 
vivo. a. Depiction of extracting BMDCs from donor Balb/c mice for genetic 
modulation of cells with lentil-viral particles to express either mCMV-Zsgreen 
or mCMV-ZSgreen-TS shRNA sequence to transplant into lethally irradiate 
Balb/c mice recipients. b. Confirmation of successful reconstitution of 
transduce BMDCs into recipient mice by PCR amplifying genomic DNA to 
detect the  Zsgreen gene and either the RNAi control or RNAi Mus TS 
sequence located between the ultramir 3’ and 5’ regions. 
.  
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that are typically found in the tumor microenvironment.  Microscopy and western 
blot analysis shown in Figure 3.3 confirm an increase in visual and protein levels 
of mCherry only in cells exposed to inflammatory stimuli INF-γ (b), LPS (c), IL1-β 
(d), or conditioned media from CT26 cells (e). In addition, western blot analysis 
quantifying mCherry protein levels confirm that protein levels of mCherry 
increased after cells were exposed to the inflammatory stimuli. The results 
indicated that regions -777 or -740 to +79 of the OPN promoter contain sites that 
are responsive to inflammatory stimuli, thus permitting it to induce the expression 
of the mCherry transcript as compared to the untreated cells (a). Western blot 
analysis showed basal levels of mCherry expression in untreated cells, but at low 
levels that will still allow the use of these promoter regions to drive the 
expression an RNAi sequence against MusTS.  
 To further analyze these regions of the OPN promoter, we transduced 
green fluorescent protein (GFP) expressing BMDCs with viral particles packaged 
with these retroviral vectors. During transduction BMDCs were exposed to stem 
cell factor (SCF), interleukin 3 (IL-3), and interleukin-6 (IL-6) cytokines and then 
plated in methylcellulose to examine colony formation and the expression of 
mCherry. Colony formation is conveyed in percentage wherein 100% of the 
colonies formed in the control and the transduced BMDCs expressed GFP, 
however transduced BMDCs expressing OPN (-777/-740 to +79) fused to GFP 
showed that approximately 50% of the GFP colonies also expressed mCherry. 
Figure 3.4 depicts the percentage of colony formation as well as the visual 
confirmation of co-localization of GFP and mCherry expression in BMDCs. From 
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this ex vivo study, we are able to validate our ability to modulate the expression 
of BMDCs, and show that the regions -777/-740 to +79 of the OPN promoter is 
responsive to inflammatory stimuli. These results also implied that genetically 
modified BMDCs expressing OPN (-777 or -740 to +79) driving the expression of 
mCherry can be used to reconstitute irradiated mice since the growth of 
progenitor  colonies showed that transduction did not affect the ability of the 
BMDCs to proliferate and differentiate. In addition, these results suggest that 
reconstitution with the modulated BMDCs will allow us to visually examine the 
activation of the OPN promoter by locating the expression of mCherry. Since, we 
have only observed activation of the OPN promoter in the presence of 
 
 
Figure 3.3: Inducible characteristic of the OPN promoter.  Retroviral vector 
containing OPN promoter region -740 to +79 driving the expression of a 
mCherry reporter gene. A-E: GP+E86 cells stably transfected with the 
retroviral vector in top panel were (A) untreated or treated with (B) IFN-ƴ, (C) 
LPS, (D) IL1-β, (E) or conditioned media. (F): Western blot showing induction 
of mCherry in response to the extracellular factors in A-E. Actin (*) was used 
as an internal control for equal protein loading. 
MSCV mCherry MSCVOPN-PrPuromycin
LPS, IFN-γ, IL1-β
GP+E86 cells
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inflammatory stimuli; these results indicate that expression of the mCherry 
protein should only occur in an inflammatory environment such as tumor regions.  
 
3.4.3 Validating reconstitution of irradiated ApcMin/+ mice with modulate 
BMDCs  
 To observe BMDCs expressing OPN (-777/-740) promoters controlling the 
expressing of mCherry in an in vivo model, we lethally irradiated existing BMDCs 
from ApcMin/+ mice. Six week post transplantation genomic DNA was extracted 
from the blood of mice and PCR amplified to confirm reconstitution with modulate 
BMDCs. Amplification of genomic DNA for mCherry expression concluded that 
we succeed in integrating the vector into the genome of mice (Figure 3.5); 
however the expression of mCherry needed validation. Thus, we sacrificed 
reconstituted mice to observe expression of mCherry within circulating BMDCs   
from the blood and in the bone marrow compartment by flow cytometry analysis. 
Even though, transduced BMDCs express GFP, we use antibodies against CD45 
for a leukocyte cell surface- marker. Flow analysis of the circulating BMDCs in 
the blood show that approximately 25% or 4% of the modulate BMDCs express 
mCherry driven by OPN promoter -740 or -777 to +79 respectively (Figure 3.6a).  
An increase expressing of mCherry was observe in the bone marrow 
compartments, showing approximately 40% and 10% for OPN promoter -740 or -
777 to +79 respectively (Figure 3.6b). The expression of mCherry in the mice 
show that the OPN promoter is functional, and since less than 50% of the 
transduced BMDCs are expressing mCherry in the blood and in the bone marrow
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Figure 3.4: Colony formation of modulate BMDCs expressing MSCV-OPN-mCherry vector. a. Percentage of GFP 
colonies that were transduced with either OPN (740/777) - mCherry retroviral particles.  50% of the GFP colonies expressed 
mCherry that were transduced with OPN (740)-mCherry viral particles, and approximately less than 50% GFP colonies 
expressed mCherry that were transduced with OPN (777)-mCherry viral particles. b. Confocal microscopy images of 
methylcellulose colonies displaying separately the expression of GFP or mCherry, and the merged co-localization expression 
of GFP and mCherry (yellow).   
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 compartment these results could be basal levels of OPN promoter activation, or 
the promoter response to systemic inflammation. This basal level of OPN 
promoter activation and mCherry expression may be problematic, for basal 
activities may cause a systemic effect when driving the expression of an RNAi 
sequence. It is essential that we determine which organs are infiltrated with 
modulated BMDCs.  This will allow us to assess the basal activity of OPN 
promoter and determine the possibility of systemic disadvantageous for future in 
vivo assays with the addition of an RNAi sequence. In addition, we expected to 
observe basal activity of OPN promoter activation in tumor burden mice, for 
these mice are prone to more inflammation.  
However if the expression of mCherry is not localized only in the tumor of 
ApcMin/+ mice, the goal of tissue specific chemo- sensitivity will be impossible to 
 
Figure 3.5: Confirming incorporation of MSCV-OPN-mCherry vectors 
in vivo.  a. Depiction of extracting BMDCs from donor C57BL/6-GFP 
expression mouse to genetically modulate the cells with retroviral particles 
to express mCherry to transplant into lethally irradiate APCMin/+ mice 
recipients. b. Confirmation of successful reconstitution of transduced 
BMDCs into recipient mice by PCR amplifying genomic DNA to detect 
mCherry gene.   
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accomplish by using the OPN promoter. Since, we observed a greater increase 
of mCherry expression driven by OPN promoter (-740 to +79) region we only 
evaluated this region of promoter in tissue sections.  Rationing that this region 
was to drive the expression of an RNAi sequence will cause the most harm 
systemically, since until now both promoter regions behave similar.  
3.4.4 Examining activation of the OPN promoter in tissues of ApcMin/+ mice 
 To determine if activation of the OPN promoter and expression of mCherry 
in the ApcMin/+mice various tissue samples, such as the spleen,  liver, lung, 
normal and tumor intestinal regions were collected to be analyzed by confocal 
microscope. Confocal microscope allows us to examine the expression of GFP 
and mCherry. Visual confirmation of GFP confirmed the infiltration of BMDCs 
within different tissue, and the visualization of mCherry expression in tissues 
provided confirmation of the OPN promoter activity. Co-localization of GFP and 
mCherry expression view by yellow shows that infiltrated transduced BMDCs in 
specific tissue is responsive to inflammatory stimuli. Our, previous data imply that 
OPN is only induced by inflammatory stimuli, thus mCherry expression should 
only be observed in the tumor regions the intestines of ApcMin/+ mice. Figure 3.5 
examining the various tissue section from control and experimental mice by 
confocal depicts images of the normal intestine regions, liver, and lung showing 
negative expression of mCherry in these tissues. Spleen tissue images show 
fluorescent background, yet we did not observe co-localization of mCherry and 
GFP expressions. On the other hand confocal images of the tumor regions in 
mice reconstituted with modified bone marrow show positive expression of 
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mCherry when compared with the control. We observe co-localization of GFP  
and mCherry expression only in the tumor regions of experimental group and not 
in control group tumor (Figure 3.6). This compelling data from confocal 
microscopy confirms that the OPN promoter is only induce in inflammatory 
environment, for the expression of the mCherry was only observed in the tumor 
regions and nowhere else in the animal. This data validates that OPN promoter 
regions (-777/-740 to +79) will permit the ability to only chemo-sensitized the 
tumor microenvironment, but only if these regions of promoter are able to drive 
the expression of an RNAi sequence.                        . 
 
Figure 3.6: Flow analysis of transduced BMDCs expressing MSCV-OPN-mCherry 
vector. a. Approximation of the percentage of transduced BMDCs that expressed either 
OPN (740/777) - mCherry in the circulation of APCMin/+ mice recipient from flow 
cytometry analysis. b. Approximation of the percentage of transduced BMDCs that 
expressed either OPN (740/777) - mCherry in the bone marrow compartment of APCMin/+ 
mice recipient from flow cytometry analysis. 
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Figure 3.7: Confocal microscopy analysis of the OPN promoter activity in various tissues. Confocal images of tissues sections 
extracted from normal regions of the intestine, spleen, liver, and lungs of APCMin/+ mice recipient. The nucleus stained by Dapi (blue), 
infiltration of BMDCs(green), expression of mCherry from BMDCs transduced with OPN(740)-mCherry (red), and co-localization 
(yellow). Infiltration of BMDCs occurred in both the normal intestinal and spleen tissues. Co-localization expression of GFP and 
mCherry was not observed in any tissue sections.  
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Control OPN(-740-+79)-mCherry
Dapi GFP mCherry Co-localization Dapi GFP mCherry Co-localization
Figure 3.8: Confocal microscopy analysis of the OPN promoter activity in the tumor region. Confocal images of tissues sections 
extracted from the tumor regions of the intestine of APCMin/+ mice recipient. The nucleus stained by Dapi (blue), infiltration of 
BMDCs(green), expression of mCherry from BMDCs transduced with OPN(740)-mCherry (red), and co-localization (yellow). Infiltration 
of BMDCs occurred in the tumor intestinal tissues. Co-localization expression of GFP and mCherry was only observed in the tumor 
section of recipients that were reconstituted with GFP BMDCs that were transduced to express OPN (740) – mCherry.  
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3.4.5 Ensuring OPN promoter aptitude to drive the expression of RNAi 
sequence against MusTS 
 We have shown that the OPN promoter (-777/-740 to +79) can drive the 
expression of the mCherry gene, but it is important to show that it has the 
capacity to drive the expression of an RNAi sequence.  Initially, we used the 
pMSCV retroviral vector in which we inserted an RNAi sequence against MusTS 
between the OPN promoter region and the mCherry transcript. An internal 
ribosome entry site placed between the RNAi sequence and the mCherry gene to 
ensure transcription of both. We established stable expression in cell lines 
GP+E86 and CHL (MUS TS) in which cells treated in the presence or absence of 
inflammatory stimuli to observe reduction of Mus TS protein levels. Unfortunately, 
we were unable to observe a reduction in Mus TS protein levels (data not 
shown). To determine if these results were correct or if there is a problem with 
the construction of the vector design, we decided to evaluate the OPN promoter 
in the pZip lenti-viral vector. To accomplish this we removed the existing the 
mCMV promoter and replace it with the OPN (-740 to +79) promoter to drive, 
such that OPN promoter would drive the expression of Zsgreen and the RNAi 
sequence against MusTS. When stably expressed in CHL (Mus TS) cells, we 
observed an appropriate phenotype.  Proteins levels of Mus TS were reduce by 
approximately 50% when compared to control and the vector control cells (Figure 
3.9a/b). Demonstrating that the OPN promoter does has the potential to drive the 
expression of an RNAi sequence. Since the OPN promoter reduces protein 
levels, better than the mCMV promoter we need to analyze if this percentage of 
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reduction effected cell proliferation. Performing a growth assay, we show that 
cells expressing the RNAi sequence against MusTS, growth rate is not retarded 
when compared to control cells or cells expressing the vector control (Figure 
3.9c). Next we examine the ability of the OPN promoter to enhance sensitivity to 
 
Figure 3.9: Examining the ability of the OPN promoter to control an RNAi 
sequence. a. Western blot analysis of CHL (Mus TS) stably transfected with pZip lenti- 
viral vector expressing either shRNA sequence or the vector control. Reduction of Mus 
TS protein is only observed in cells transduced with the silencing sequence. b. 
Quantification of the Mus TS protein shows the shRNA sequence reduces the 
expression of Mus TS protein by approximately 50%. c. Growth curve graph indicating 
that the growth rate of cells expressing the shRNA sequence is comparable to control 
cells or the cells expressing the vector control. d. Growth inhibition assay show that 
pZip vectors exhibit sensitivity to 5-FU therapy.  
 
a.
b.
c. d.
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5-FU by treating cells that expressed either the pZip-OPN-shRNA or pZip-OPN 
control vector with increasing concentration of 5-FU to observe growth inhibition. 
Cells that were not transfected with either of the pZip vectors was used as an 
addition control to confirm that the vector control does not affect cellular 
response to 5-FU. Results indicate that cells that are expressing the RNAi 
sequence against MusTS under the control of the OPN promoter are more 
sensitive to 5-FU therapy in comparison to the vector control and control cells 
 
Figure 3.10: Examining Zsgreen expression a. Microscopy images of cells 
transduced to express pZip-OPN-vector and pZip-OPN-shRNA vector to observe 
Zsgreen expression in cells. b. Flow cytometry analysis of cells transduced to 
express pZip-OPN-vector and pZip-OPN-shRNA vector to quantify Zsgreen 
expression in cells. c. Western blot analysis to quantify protein expression of 
Zsgreen in transduced cells.  
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(Figure 3.9d). These premises further assure the advantage in using the OPN 
promoter to establish tissue specific chemo-sensitivity and drive the expression 
of RNAi technology.  
Additional, we determine that the expression of the RNAi sequence does 
not corresponds to the expression of Zsgreen fluorescent marker under the 
control of the OPN promoter. With microscopy and flow cytometry analysis, we 
show that cells transduce to expression pZip-OPN vector control has a higher 
percentage of cells expression Zsgreen compared to cell transduce to express 
the pZip-OPN-shRNA vector (Figure 3.10a and b). Indicating that some cells in 
the pZip-OPN-shRNA group expresses the shRNA sequence, however the 
Zsgreen marker is silent. Results show that approximately 78% of the cells 
transduced to express pZip-OPN vector expressing the Zsgreen fluorescent 
protein, however only approximately 48% of the cells transduced to express the 
pZip-OPN-shRNA vector expresses the Zsgreen fluorescent protein. The 
expressing of the Zgreen protein in almost half expressed in the cell that were 
are expressing the RNAi sequence against MusTS, however most importantly 
these cells have been shown to be highly sensitivity to 5-FU treatment. This is 
significant result because this demonstrates that cells do not have to express 
Zsgreen to be more sensitive to 5-FU therapy.  
3.4.6 Examining the apoptotic indices of modulate CHLT (MusTS) cells 
 To determine if we were able to enhance apoptosis in cells expressing the 
pZip-OPN-shRNA vector in comparison to the controls we treated the cells with 
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500nM or 10000nM of 5-FU for 5 days. These two concentration were used 
because 500nM of 5-FU is the concentration to 5-FU needed to inhibit 50% cell 
growth in cell expressing the pZip-OPN-shRNA vector previously shown in Figure 
3.9c; and 10000nM of 5-FU was used because this concentration would ensure 
that we would observe apoptosis in cells. We decided to use flow cytometry 
analysis staining cells with Annexin V and viability dye antibodies. Using both of 
these antibodies together, we were able to obtain late apoptotic indices (Annexin 
V and viability dye positive cells) and early apoptotic indices (Annexin V only 
positive cells). In addition, we were able to determine the apoptotic indices of 
Zsgreen cells by identifying cells that express Zsgreen and Annexin V antibodies. 
The result from this study are displayed in fold changes comparing the no treated 
cells with the cells treated with either 500nm or 10000nM of 5-FU. For the late 
apoptotic indices we observe a 0.5, 0.2, and 0.7 fold change increase in cells 
treated with 500nM 5-FU for CHLT (Mus TS) control cells, cells transduced with 
pZIP-OPN vector control, and cells transduces to express pZip-OPN-shRNA 
vector respectively. The major fold change increase for late apoptotic indices 
occurred when cells were exposed to 10000nM 5-FU. These fold change 
increase are 5.0, 2.2, and 4.7 for  CHLT (Mus TS) control cells, cells transduced 
with pZIP-OPN vector control, and cells transduced to express pZip-OPN-shRNA 
vector respectively (Figure 3.11a). Even though, we did not observe a 
significance in the apoptotic indices for late apoptosis we do indeed observe a 
significant difference in the early apoptotic indices in cells treated with the highest 
concentration of 5-FU. Results show increase fold changes of 26.1, 20.7, and 
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59.7 for  CHLT (Mus TS) control cells, cells transduced with pZIP-OPN vector 
control, and cells transduced to express pZip-OPN-shRNA vector respectively 
(Figure 3.11b). These results show that cells transduced to express the pZip-
OPN-shRNA vectors are highly apoptotic compared to the control, Thus 
confirming the RNAi sequence against MusTS is enhancing cellular sensitivity to 
5-FU. Upon, investigating the apoptotic indices in Zsgreen expressing cells 
results also show that cells expressing the RNAi sequences are highly more 
 
Figure 3.11: Apoptotic indices of transduce CHLT (MusTS) cells. a. The late 
apoptotic indices of cells treat with 5-FU. b. The early apoptotic indices of cells 
treated with 5-FU. c. The apoptotic indices of cells expressing Zsgreen. d. Western 
blot analysis of Parp-1 protein expressing from cells treated in the absence or 
present of 500nM of 5-FU.  
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apoptotic than cells that are expressing on the vector control. The fold change 
increase are 17.2 and 50.6 for pZip-OPN- vector control and pZip-OPN-shRNA 
vector respectively (Figure 3.11c). In addition western blot analysis of Parp-1 
protein expression show and increase in cells treated with 500nM 5-FU when 
compared to cells that are not expose to the drug (Figure 3.11d). The premise of 
these finding confirms the ability to establish chemo-sensitivity within the TME.  
3.4.7 Examining the apoptotic and proliferation indices of modulate BMDCs 
in Balb/c CT26 subcutaneous tumor model  
 To evaluate if the tissue specific chemo-sensitivity can be achieved by 
using the OPN promoter we performed an acute study which involve lethally 
irradiated Balb/c mice and reconstituted with BMDCs that expressed the pZip 
vector that contain Zsgreen and TS RNAi sequence driven by the OPN (-740 to 
+79) promoter. Controls for this study were Balb/c mice reconstituted with 
BMDCs that expressed the vector control that contain the Zsgreen gene under 
the control of the OPN promoter or GFP BMDCs. Four weeks post reconstitution 
mice with modulated BMDCs; genomic DNA was extracted from the blood to 
confirm incorporation of the Zsgreen gene in the genome (Figure 3.12). Six 
weeks post reconstitution CT26 colon cancer cells was injected in the flank of 
these mice. Tumors were allowed to grow to approximate 10-12mm diameter 
before mice were subjected to a single i.p. injection of either PBS or 50mg/kg 5-
FU. Tumors average growth rates shown in Figure 3.12. We did not observe 
significant reduction in the growth of tumors in the experimental groups in 
comparison with the controls, which is expected since mice were only exposed to 
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a single injection of 50mg/ kg of 5-FU. Five days post therapy mice were 
sacrificed to collect the tumor for flow analysis to determine apoptotic and 
proliferation indexes in CD45+ immune cells, T cytotoxic cells (CD8a/CD8b), 
mast cells (CD34/CD117), MDSCs (Gr1/CD11b), and T regulatory cells 
(CD4/Foxp3). We decided to obtain data five days post therapy, for previous 
result from our lab observed reduction in MDSCs, moderate effect in  Tregs cells,  
 
Figure 3.12: Confirming incorporation of pZip-OPN lenti-viral vectors in 
vivo.  a. Confirmation of successful reconstitution of transduce BMDCs into 
recipient mice by PCR amplifying genomic DNA for the incorporation of the 
Zsgreen and either the RNAi control or RNAi Mus TS sequence located 
between the ultramir 3’ and 5’ regions from the pZip-OPN control vector or of 
pZip-OPN-MusTS shRNA vector. b. CT26 cells tumor growth rate in mice 
that were reconstituted with modulate BMDCs or control BMDCs.   
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and resistance in mast cells in the tumor bed of Balb/c mice in a time course 
treatment study for ten days to observe BMDCs response to 5-FU in this 
advance colorectal model. The quantity of MDSCs and Tregs within the CT26 
tumor in Balb/c mice displayed a 0.5 fold change five day after a single dose of 5-
FU. Recovery for both these cells type were back to normalcy by day 7. 
Conversely, mast cells displayed a two folds increase within the tumors five days 
after 5-FU exposure and returned to basal level at day 7 (unpublished data 
Acharya, Grishma). Using this prior data as the initial point of interest, we expect 
to observe an enhancement in the reduction of MDSCs and Treg cells in 
response to 5-FU, but most importantly we expect to observe sensitivity of tumor 
mast cells to 5-FU in mice that are reconstituted with the genetically modulated 
BMDCs. In addition to these three cell types we decide to observe the effects of 
5-FU on CD45+ immune cells and cytotoxic T cells (Tc cells). Observing the 
response of the broad spectrum of immune cells, in particular CD45+ cells may 
provide a better depiction of the effect of 5-FU on BMDCs.  Additionally, 
observing the effects of 5-FU on Tc cells will provide a depiction of how 5-FU 
disrupts antitumor immunity activities, which are typically performed by these 
cells.  
Figure 3.13 represents the flow analysis, which provides the percentages 
of cells that are positive for the surface markers to identify the different cell types. 
In similarity with our previous acute time course study, we observed 
approximately 10% reduction in the MDSCs cell population five day post 5-FU 
subjection in the control and vector control groups when compared to the cohorts 
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subjected to PBS. However, the percentage of tumor MDSCs increased 
approximately 7% in mice transduced with BMDCs expressing the shRNA vector 
and exposed to 5-FU compared to the mice transduced with BMDCs expressing 
the shRNA vector and subjected to PBS (Figure 3.13a). Examination of the tumor 
Tregs show an approximately 3%, 1.5%, and 2% increase in animals treated with 
5-FU for control, OPN vector control, and OPN-shRNA vector groups 
correspondingly compared to respective PBS animals (Figure 3.13b). Figure 3.13 
c demonstrates an increase in tumor mast cells for the control and OPN-shRNA 
vector groups, approximately 2% and 10% respectively. However, for the OPN 
vector control and 5-FU treated mice, tumor mast cells were reduced 
approximately 1.5%. Behaving similarly to Tregs we observed an increase of 
tumor Tc cells in all groups, approximately 3%, 0.5%, and 5% for the control, 
OPN vector control, and OPN-shRNA vector mice expose to therapy 
correspondingly (Figure 3.13 d). Lastly, resembling the trend of tumor MDSCs we 
observed reduction of tumor CD45+ immune cells in both the control and OPN 
vector control 5-FU treated mice, approximately 16% and 5% respectively. 
However, an approximately 20% increase occurred in mice transduced with 
BMDCs expressing OPN-shRNA vector and treated with 5-FU compared to PBS 
cohorts (Figure 3.13 e).  
Advance, flow analysis permitted examination of the total apoptotic and 
proliferation indices of each of these cell types. Additionally, the total apoptotic 
and proliferation populations further evaluation is accomplish by dividing the 
population into two subgroups: Zsgreen positive or Zsgreen negative apoptotic 
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and proliferative populations, which are depicted by the percentages bar graphs 
in Figures 3.14-3.18. The Zsgreen positive population identifies modulated 
BMDCs expressing either the OPN vector control or the OPN-shRNA vector. The 
double stained surface markers plus Zsgreen positive or Zsgreen negative 
Detection of AnnexinV antibody determined the apoptotic index, and detection of 
intercellular levels of ki67 determined the proliferation index for each target cell 
types. 
Firstly, examining the of total apoptotic index of tumor MDSCs show that 
the percentage of apoptotic MDSCs decrease in the tumor of control mice treated 
with 5-FU in comparison to the PBS cohorts, however the apoptotic percentages 
of tumor MDSCs in mice reconstituted with transduced BMDCs expressing either 
lenti-viral vectors display an increase of apoptotic tumor MDSCs. There is a 3% 
and 16.8% increase of apoptotic tumor MDSCs in mice subjected to 5-FU in OPN 
vector or OPN-shRNA vector groups respectively, when compared to PBS 
cohorts (Figure 3.14 a). Notably the proliferation of tumor MDSCs does not 
decrease for any of the groups after 5-days post 5-FU treatment. The percentage 
of proliferative MDSCs for the PBS and 5-FU cohorts in the control group are 
similar; and a proliferative increase of a 4.4% and 17.5% occurred in OPN vector 
control and OPN-shRNA vector - 5-FU treated animals respectively, paralleled to 
PBS cohorts (Figure 3.14 b). Only for the 5-FU control group was there a 4.6% 
increase in the percentage of tumor Tregs, and no change in the percentage of 
proliferative tumor Tregs for this group when equated to control PBS mice. Yet 
there was a slight decrease of 1.5% or no variation in the percentage of apoptotic 
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Tregs in OPN vector control or OPN-shRNA vector  reconstituted animals treated 
with 5-FU, however the proliferative percentage of Tregs does increase by 9% or 
3.8% for each respective groups compared to PBS mice (Figure 3.15). 
Highlighting that the percentage of apoptotic tumor mast cells only displayed a 
percentage increased in mice reconstituted with BMDCs expressing the OPN-
shRNA vector and treated with 5-FU by 2.6% elevation compared to the PBS 
cohorts. The other 5-FU treated mice for control and the OPN-vector control 
showed a decreased in the percentage of apoptotic tumor mast cells when 
compared to PBS associates. However, an increase in the total percentage of 
proliferative tumor mast cells occurred in OPN vector control and OPN-shRNA 
vector groups that were exposed to 5-FU, whereas a reduction was seen in the 
control 5-FU group ( Figure 3. 16). Observing the percentage of tumor apoptotic 
Tc cells result show a decrease for both control and OPN vector control, 3.6% 
and 7.4% reduction respectively, however, result show an increase of 12.5% for 
the OPN-shRNA vector reconstituted animals when equated to the 
corresponding PBS treated mice. All groups displayed a reduction in the 
percentage of tumor proliferative Tc cells (Figure 3.17). Lastly, examining the 
percentage of apoptotic CD45+ immune cells in the tumor after 5-FU treatment 
show an increase for all groups compared to the PBS treat animals. The increase 
of apoptotic CD45+ immune cells is 0.5%, 1.2%, and 9.7% for control, OPN 
vector control, and OPN-shRNA vector 5-FU treated mice respectively. Only the 
proliferative percentage for CD45+ immune cells increased by 15.2% for mice 
reconstituted with BMDCs expressing the OPN-shRNA vector and subjected to 
  89  
 
5-FU, whereas the decrease in the percentage of proliferative CD45+ immune 
cells was observed in the control and OPN-vector control 5-FU subject mice 
compared to PBS counterparts ( Figure 3.18). 
Advance analysis of the apoptotic and proliferative indices of each cell 
types by dividing the total percentage of indices into subgroups dependent on 
present or absent of Zsgreen expressing will indicate if modulate BMDCs 
expressing the shRNA sequence is more sensitive to 5-FU therapy. It is 
important to note that expression of Zsgreen does not determine correlate with 
expression of the shRNA sequence against TS. For we did not determine the 
difference of expression of TS protein levels in Zsgreen or non-Zsgreen cell 
types. Thus, briefly examining the of apoptotic indices of MDSCs, mast cells, 
Tregs cells, and Tc cells that are Zsgreen positive result show no increase the 
percentage of apoptotic cells after 5-FU treatment compared to PBS. However, 
examining the non-Zsgreen cells of each of these cell types that are transduced 
to express the shRNA show an increase in the apoptotic indices compared to the 
PBS group, thus suggesting the shRNA may be expressed in some of the non-
Zsgreen cells and thus enhance cellular sensitivity to 5-FU treatment. Also, to 
confirm this implication analyzing the result for the CD45+ immune cells 
modulated to express OPN-shRNA vector, result shows that in both subgroups 
Zsgreen positive and negative cells after 5-FU therapy increases the percentage 
of apoptotic CD45+ immune cells equated to the PBS treated cohorts.  
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Figure 3.13: Flow analysis of tumor BMDCs populations. a. The total percentage of tumor MDSCs double stained with 
CD11b and Gr1 antibodies. b. The total percentage of tumor regulatory T cells stained with CD4 and Foxp3 antibodies. c. The 
total percentage of tumor mast cells stained with CD34 and CD117 antibodies. d. The total percentage of tumor cytotoxic T 
cells stained with CD8a and CD8b antibodies. e. The total percentage of CD45+ immune cells stained with CD45 antibody.  
Each graph include mice reconstituted with non- transduce BMDCs (Control), or mice reconstituted with BMDCs expressing 
either the OPN- vector control (OPN), or OPN-shRNA vector (OPN-shRNA). Each of these engraftment groups are subdivided 
into two groups of animals either exposed to PBS for the control or to 50mg/kg of 5-FU for the treatment and experimental 
group.  
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Figure 3.14: Apoptotic and proliferation indices for tumor MDSCs. a.  The apoptotic indices of tumor MDSCs for mice either 
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-
shRNA vector (OPN-shRNA). b. The proliferative indices of tumor MDSCs for mice either reconstituted with non-transduced 
BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPN-shRNA). Mice 
reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.  
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Figure 3.15: Apoptotic and proliferation indices for tumor Tregs cells. a. The apoptotic indices of tumor Tregs cells for mice either 
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-
shRNA vector (OPN-shRNA). b. The proliferative indices of tumor Tregs cells for mice either reconstituted with non-transduced 
BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPN-shRNA). Mice 
reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU. 
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Figure 3.16: Apoptotic and proliferation indices for tumor mast cells a. The apoptotic indices of tumor mast cells for mice 
either reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or 
OPN-shRNA vector (OPN-shRNA). b. The proliferative indices of tumor mast cells for mice either reconstituted with non-
transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPN-
shRNA). Mice reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU. 
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Figure 3.17: Apoptotic and proliferation indices for tumor Tc cells.  a. The apoptotic indices of tumor Tc cells for mice either 
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-
shRNA vector (OPN-shRNA). b. The proliferative indices of tumor Tc cells for mice either reconstituted with non-transduced BMDCs 
(Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPN-shRNA). Mice reconstituted 
with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.  
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Figure 3.18: Apoptotic and proliferation indices for CD45+ immune cells. a. The apoptotic indices of tumor CD45+ immune 
cells for mice either reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector 
control (OPN) or OPN-shRNA vector (OPN-shRNA). b. The proliferative indices of tumor CD45+ immune cells for mice either 
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-
shRNA vector (OPN-shRNA). Mice reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.  
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Since, the percentages of apoptotic cells were higher than expected from the 
flow analysis. We further analyze the apoptotic indices of some cells by confocal 
imagery. Unlike flow analysis, we were unable to stain with two surface markers 
to identify the different cell types.  Thus, for MDSCs we stained for both 
granulocytes and monocytes by using antibodies against surface markers Ly-6 
and Cd11b respectively, antibodies against surface marker c-kit was used to 
identify mast cells, and to determine the apoptotic cells we stained with cleaved 
PARP-1. Thus, the combination of one surface marker and cPARP-1 antibodies 
were used to determine the apoptotic indices of Ly-6 positive granulocyte, CD11b 
positive monocytes, and c-kit positive mast cells. The apoptotic indices for each 
of these cells are express by the percentage of the cells stained positive for both 
the surface marker and a cPARP-1 antibody, which was accomplished by 
counting 100 field views for each cell type, and PBS treated mice, were used to 
determine apoptotic baseline of each cell type. Figure 3.19 shows the apoptotic 
indices for Ly-6 cells, and results show that 5-FU treated mice apoptotic indices 
increases approximately 6% and 14% for mice reconstituted with BMDCs 
transduce to express pZip-OPN vector control or pZip-OPN-shRNA vector 
respectively. This same trend is observed in CD11b positive cells showing 
approximately an 8% and 17% increase (Figure 3.20), and for c-kit positive cells 
showing approximately, a 3% and 7% increase for mice treated with 5-FU and 
engrafted with modulate BMDCs (Figure 3.21). In comparing 5-FU, treated 
animals we show that mice engrafted with BMDCs expressing the shRNA vector 
had more apoptotic monocytes, granulocytes, and mast cells.  Even though, 
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these are promising results, we were unable to determine which of the Ly6, 
CD11b, and c-Kit positive cells were transduced to express either the pZip-OPN 
vector control or the pZip-OPN-shRNA vector. Due to the inability to distinguish 
the real signal of Zsgreen in the Fittc channel from the confocal microscopy 
analysis, we are unable to quantify the number of cells that are transduced. 
Therefore, are unable to determine if the transduced cells expressing the RNAi 
sequence are highly apoptotic cells when compared to the controls. However, we 
are able to infer this data by combining results from our flow analysis with our 
results from our confocal microscopy analysis. From our flow analysis, we are 
able to determine the percentage of cells that are positive for both Zsgreen and 
MDSC or mast cell markers, and by using this percentage has a reference to 
infer the percentage of Ly6, CD11b, or c-Kits positive stained cells from confocal 
microscopy analysis which maybe Zsgreen. Theoretically, this is logically since 
these are the same tumors samples for both flow and confocal microscopy 
analysis. These inference results in Figure 3.22 show the difference between 
cells transduced to express the pZip-OPN vector control and the pZip-OPN-
shRNA vector.  Results show that Zsgreen Ly6 positive cells treated with 5-FU 
has either   a 5% or 11% increase  in mice engrafted with BMDCs expressing 
pZip-OPN vector control or pZip-OPN-shRNA vector respectively (Figure 3.22a).  
Figure 3.22 b and c show the same trend observed in Zsgreen CD11b 
demonstrated a 7% or 13% increase, and for Zsgreen c-Kit positive cells a 0% or 
5% increase for samples that expressed the pZip-oPN vector control or the pZip-
OPN-shRNA vector respectively.                                     .                                                                               
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Figure 3.19: Apoptosis induced in granulocytes at 5 days after 5-FU administration. Tumor tissues from reconstituted Balb/c 
mice were stained with rat monoclonal primary antibody againstLy-6 and rabbit polyclonal primary antibody against c-PARP-1. The 
samples were then incubated with Cy-3-conjugated donkey anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit 
secondary antibody, respectively. 100 total images were taken for both PBS and 5-FU samples... a. Representative field views of 
confocal images of tumor sections from PBS and 5-FU treated mice are shown.  Green = Gr-1 positive cells (granulocytes), Red = 
cleaved PARP-1 (apoptotic cells). Double positive cells indicate apoptotic granulocytes. b. Percentage of apoptotic Ly-6 cells in the 
tumor tissues of mice reconstituted with modulated BMDCs.  
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Figure 3.20: Apoptosis induced in monocytes at 5 days after 5-FU administration. Tumor tissues from reconstituted Balb/c 
mice were stained with rat monoclonal primary antibody againstCD11b and rabbit polyclonal primary antibody against c-PARP-1. 
The samples were then incubated with Cy-3-conjugated donkey anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit 
secondary antibody, respectively. 100 total images were taken for bothPBS and 5-FU samples. .a. Representative field views of 
confocal images of tumor sections from PBS or 5-FU treated mice are shown.  Green = CD11b positive cells (granulocytes), Red = 
cleaved PARP-1 (apoptotic cells). Double positive cells indicate apoptotic monocytes. b. Percentage of apoptotic CD11b cells in 
the tumor tissues of mice reconstituted with modulated BMDCs 
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Figure 3.21:  Apoptosis induced in mast cells at 5 days after 5-FU administration. Tumor tissues from reconstituted Balb/c 
mice were stained with rat monoclonal primary antibody against c-Kit and rabbit polyclonal primary antibody against c-PARP-1. The 
samples were then incubated with Cy-3-conjugated donkey anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit 
secondary antibody, respectively. 100 total images were taken for both PBS and 5-FU samples. a. Representative field views of 
confocal images of tumor sections from PBS or 5-FU treated mice are shown.  Green = c-kit positive cells (mast cells), Red = 
cleaved PARP-1 (apoptotic cells). Double positive cells indicate apoptotic monocytes. b. Percentage of apoptotic c-kit cells in the 
tumor tissues of mice reconstituted with modulated BMDCs 
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Figure 3.22:  Theoretical apoptotic indices of modulate BMDCs expressing Zsgreen. This data is theoretical data from flow 
cytometry analysis taking the percentage of positive Zsgreen cells to determine the number of cell of positively stained cell  by 
confocal analysis is Zsgreen positive.  a. Theoretical percentages of apoptotic indices of Zsgreen and Ly6 positive cells from 100 
field views. b. Theoretical percentages of apoptotic indices of Zsgreen and CD11b positive cells from 100 field views. c. Theoretical 
percentages of apoptotic indices of Zsgreen and c-Kit positive cells from 100 field views.  
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3.5 DISCUSSION:   
To be able to establish tumor specific chemo-sensitivity to TS inhibitors it 
was necessary to identify an RNAi vector system that does not exhibit cytotoxic 
effect in vivo. For our previous studies, which used the retroviral pSuper vector to 
establish constitutive expressing of a silencing sequence suggest we had the 
ability to examine systemic effects reducing TS protein levels in vivo. However, 
introduction of transduce BMDCs expressing this RNAi system in ApcMin/+ mice 
demonstrated detrimental results, in that none of the mice survived engraftment. 
The effects from our prior result points out the importance of identifying an RNAi 
vector system that has the capacity to be used for in vivo studies. Therefore, we 
decided to employ the pZip-mCMV lenti-viral RNAi vector system, for this system 
contains resemblance characteristics of endogenous pri-miRNA. Mechanistically 
allowing the embedded shRNA to be processed by endogenous RNA-induced 
silencing complex. Additionally, this system uses the polymerase II promoter 
mCMV to control the expression of the shRNA, permitting the ability to observe in 
vivo systemic effects cause by the reduction of TS protein levels. Result from this 
study confirms that the mCMV promoter does have the capacity to control and 
RNAi sequence to suppress the expression of TS protein levels in vitro. 
However, does not have the ability to reduce protein levels enough to establish 
or enhance sensitivity to 5-FU displays by our growth inhibition assay results.  
Despite this system inability to enhance sensitivity in vitro, it is essential to 
investigate its potential of introduction into an in vivo cancer model. Indeed, 
results confirmed that transduced BMDCs expressing this vector system could be 
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introduced into lethally irradiated Balb/c mice without exhibiting any cytotoxic 
effect to the mice. Since in vitro studies were unsuccessfully in providing 
enhance sensitivity to therapy, we presume the same result would occurred in 
vivo. Conversely, we succeeded in identifying an RNAi vector system that 
exhibits the capacity to modulate BMDCs by lessen the expression of cellular TS 
for in vivo studies.  
Thus, proceeding forward to enhance cellular response to tumor specific 
TS target therapy we decided to examine the functionality and aptitude of the 
OPN promoter.  Prior studies by Denhardt and colleagues examined and 
investigated regions within the promoter that contain enhancers that are 
responsive to pro-inflammatory stimuli. Exploiting the inducible characteristic of 
the OPN promoter, we elect to use this promoter to establish tumor specific 
chemo-sensitivity. Nonetheless, before using this promoter to establish sensitivity 
it was necessary to determine if this promoter functionality would only be active 
within the TME; and indeed our results demonstrated that  expression of 
mCherry protein driven by region -740 to +79 of the OPN promoter was only 
located in the tumor regions of intestinal tissues of ApcMin/+   mice. Confirming 
activation of the OPN promoter only occurred within the tumor regions was 
essential for our strategy to achieve tumor specific chemo-sensitivity.  
As important to determine the functionality of the OPN promoter, it was 
also necessary to determine its aptitude to drive the expression of the RNAi 
silencing sequence against TS. Thus, to investigate OPN promoter potential we 
elected to use the pZip-lenti-viral RNAi vector system, for which the OPN 
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promoter replaces the mCMV promoter. Our result illustrates OPN promoter 
ability to control the expression of a silencing sequence, and is able to establish 
significant reduction of cellular MusTS cellular unlike the mCMV promoter.   In 
addition, we were able to establish enhance cellular sensitivity with the OPN 
promoter controlling the expression of TS silencing sequence, and so we 
acquired all the essential components to modulate BMDCs, such to investigate 
the ability to enhance efficacy of therapy within in the TME.  
Although, we have the necessary components to establish tumor specific 
chemo-sensitivity our approach demonstrates inadequacies and the need for 
revisions in order to observe the optimal effects of this particularly therapy. For 
we successfully modulate BMDCs to express pZip-OPN vectors in a 
subcutaneous cancer mouse model, however the verdict of established tumor 
specific chemo-sensitivity to 5-FU needs further investigation and evidence. To 
begin we decide to use flow cytometry analysis to determine the difference of 
apoptotic indices for MDSCs, mast cells, Tregs, Tc cells, and CD45+ immune 
cells. However, the percentage of apoptotic cells for each cell types is rather high 
than expected for the PBS treated mice, thus comparing the effect of 5-FU was 
difficult to determine.  A possible explanation for such high apoptotic percentages 
could be, due to the multiple step staining procedures need to identify each cell 
types apoptotic indices.  In the samples, processing the integrity of the cell 
membrane may have been disturbed, causing higher percentages of apoptotic 
cell populations.  
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On the other hand, examining the total proliferative indices of cell types 
MDSCs, Tregs cells, mast cells, and CD45+ immune cells results show an 
increase in proliferation after subject to 5-FU in BMDCs expressing the OPN-
shRNA vector. These results are alarming for expected results should display a 
decrease in proliferation within these cells type in comparison to the PBS treated 
mice. A possible explanation is that these results are illustrating residual 
response of 5-FU treatment, such that the system is attempting to recover from 
5-FU effects by increase the proliferation.  
The results from our flow analysis study did not provide any clear 
indication that we have accomplished tumor specific chemo-sensitivity, for our 
initially had approach flaws. For this, we decided to examine the apoptotic 
indices of MDSCs subgroups granulocytes and monocytes cells and mast cells 
by confocal analysis. For MDSCs are  highly responsive to 5-FU therapy and 
mast cells exhibits minimal to no responsiveness to 5-FU therapy, and thus by 
examining these cells types we would be able to determine if we establish 
specific chemo-sensitivity and enhance the efficacy of 5-FU therapy within the 
TME. Our results demonstrate an increase in apoptotic indices for granulocytes, 
monocytes, and mast cells in 5-FU treated mice when compared to respective 
PBS treated mice. Most importantly, we observed higher apoptotic indices in 
mice reconstituted with BMDCs expressing the pZip-OPN-shRNA vector than 
with pZip-OPN vector control. This is promising data because we demonstrate 
the ability to enhance the efficacy of 5-FU within the TME of an in vivo cancer 
model. Unfortunately, with our confocal microscopy analysis we were unable to 
 106 
 
distinguish which of the positive stained cells expressed the pZip vectors, for we 
were unable to determine the real signal of Zsgreen expression in the FITTC 
channel due to auto-fluorescent background signaling. Alternatively, we 
attempted to stain for Zsgreen with antibodies to quantify the number of cells 
triple positive (surface marker, apoptotic marker, and Zsgreen positive), however, 
there was only one antibody against Zsgreen on the market, and it did not 
successfully work for staining, for it known applications were for western blot and 
immunoprecipitation analysis. Such that we decide to theoretically, conclude our 
results from the animal studies by using data from both our flow cytometry and 
confocal microscopy studies. In theory, the same tissue samples used for both 
studies; therefore, the percentage of Zsgreen cells determined from the flow 
cytometry analysis is the same percentage of positive cells for the confocal 
analysis. Using these percentages, we were able to theoretically inference the 
percentage of Ly6, CD11b, or c-Kit positively stained cells that are also Zsgreen 
positive. From these results, again we were able to inference that mice 
reconstituted with BMDCs expressing the pZip-OPN-shRNA vector had a higher 
apoptotic indices than mice reconstituted with BMDCs expressing the vector 
control.  
Even though, our confocal microscopy and theoretical results are 
promising, the results were not significant. Possible reasoning is that mice were 
reconstituted with twenty percent of modulated BMDCs. It is possible to enhance 
sensitivity by reconstituting mice with either a higher percentage or 100% of 
modulated BMDCs expressing the pZip-OPN-shRNA vector.  Additionally, it is 
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necessary to determine if the Zsgreen expression correlates with shRNA 
expression, to accomplish this, transduced BMDCs needs to sorting into two 
populations Zsgreen positive and negative, such to measure and compare the 
differences of mRNA and/ or protein in the two populations. These results will 
provide a better depiction of the expression of the shRNA. Importantly, to 
examine the ability to enhance the effect of 5-FU therapy more acute studies are 
necessary at different time points post therapy to gain and assess the overall 
response of genetic modulate BMDCs to 5-FU therapy.  
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CHAPTER 4 
 
THE EFFECTS OF MAST CELL INHIBITION ON TUMOR RESPONSE IN 
APCMIN/+ MICE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________ 
3The Effects of Mast Cells Inhibition on Tumor Response to 5-FU in  
ApcMin/+mice, Nikeya L. Tisdale, Celestia Davis, Maria Marjorette O. Peña. 
To be submitted.                                                                                                                 
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4.1  ABSTRACT: 
Mast cell precursors originate in the bone marrow and migrate through the 
blood into tissues where terminal differentiation and maturation occurs. They are 
essential for inflammatory stimuli, and when activated, release an array of 
cytokines and molecules. In response to treatment with 5-fluoruracil (5-FU), an 
inhibitor of the enzyme thymidylate synthase that is used in the clinical 
management of colorectal cancer, we found that mast cells are recruited into the 
tumor’s beds in ApcMin/+mice, where they may play a role in tumor recurrence 
post therapy. Because of this, we examined the possibility that pharmacological 
inhibition of mast cells might play a synergistic role when combined with 5-FU. 
The objective of this study is two-fold: 1) to determine if pharmacological 
inhibition of mast cells can interfere with tumor development, and 2) to determine 
if mast cell inhibition can enhance the antitumor effects of 5-FU or prolong tumor 
recurrence post therapy. ApcMin/+ mice were subjected to a regimen of 5-FU or 
Cromolyn, a mast cell inhibitor, alone or in combination. Findings suggest that 
inhibition of mast cells can influence tumor development, but has little impact on 
tumor recurrence after therapy.  
 
4.2 INTRODUCTION: 
 Tumors are complex organs consisting of a heterogeneous population of 
both cancer and host-derived non-cancer cells interactions. These non-
neoplastic cells compose the tumor stroma and play a critical role in tumor 
initiation, progression, and response to therapy. Hence, effective anti-cancer 
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therapies should target not only the tumor cells but also the non-tumor cells, 
which may contribute to tumor resistance during therapy or its recurrence post 
therapy.  
 Tumor recurrence or resistance to TS inhibitors has been a major problem 
for many years. A previous study by Tucker et. al., systemically treated ApcMin/+ 
mice with 5-FU. Results showed reduction in tumor burden, yet when treatment 
is ceased, tumor recovery is induced (Tucker, Davis et al. 2002). This result 
could potentially be influence by the associate BMDC such as mast cells that 
infiltrate or surround the tumor in a protective manner. In addition to this study 
unpublished data from our lab showed that a single dose of 5-FU (50mg/kg) 
administered to ApcMin/+ mice reduced the number of tumor associated MDSC 
and regulatory T cells, but mast cells were still recruited to the tumor bed 
(Acharya, unpublished data). Implicating, mast cells potential to be effector cells 
that may influences tumor resistance and recurrence post 5-FU therapy. 
 Mast cells are effectors cells that play major role in inflammation, allergic 
reactions, and wound healing mechanism. Their precursors are release from the 
bone marrow compartment as immature cells, allowed to migrate into various 
tissues within the body to undergo maturation and differentiation. Maturation and 
differentiation is influence by the tissue environment for which infiltrated, resulting 
in a heterogeneity population, which can be promising for the development of the 
tumor, such that the TME can influence the maturation of the mast cells to assist 
in tumor progression. Mast cell pro-tumor responses are dependent on the type 
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of cancer and the stage of the tumor development (Groot Kormelink, 
Abudukelimu et al. 2009; Ribatti 2013; Oldford and Marshall 2014) 
 Several studies have examining mast cells pro-tumorigenic role in mouse 
models. Gounaris et al. have shown that mast cells infiltrate the 
microenvironment of gastrointestinal polyps in three mouse models, which 
include the ApcMin/+ mouse, and that mast cells are require and essential for the 
initial stages of adenoma development (Gounaris, Erdman et al. 2007). Another, 
study showed that performing adoptive transplant of naive Tregs from healthy 
mice into APC∆468 mice reduces mastocytosis, resulting in a reduction of tumor 
burden (Gounaris, Blatner et al. 2009). A study demonstrates that deletion of 
mast cell 5-Lipoxgenase (5-LO), a pro-inflammatory mediator, proved to reduce 
tumor numbers, resulting in the mitigation of MDSCs in the polyps of APC∆468 
mice (Cheon, Khazaie et al. 2011; Cheon, Strouch et al. 2012). These particular 
studies, show that mast cells are associated with tumor development and 
progression, and should be potential target when combating cancer. 
 One potential way to target the pro-tumorigenic functions of mast cells is 
to inhibit mast cells degranulation by administering a pharmacological drug, 
Cromolyn. Cromolyn is classified as a mast cell stabilizer that blocks mast cells 
degranulation by indirect inhibition of the influx of calcium by blocking chloride 
channels within the cells(Matthews, Neher et al. 1989; Norris and Alton 1996). 
The exact mechanism of inhibition is poor understood. However, several studies 
have administered Cromolyn to cancer mouse models and have observed 
promising effects. A study, by Souceket.al indicates the mast cells infiltrates and 
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assists with the expansion of Myc-induced pancreatic tumors. However, upon 
inhibition of mast cell degranulation with Cromolyn resulted in reduction of tumor 
islet expansion. (Soucek, Lawlor et al. 2007). Another, study subcanteously 
injected well-differentiated prostate cell line into the flank of mice, to allow tumor 
development. These mice were subjected to Cromolyn daily for three weeks, and 
treatment with Cromolyn showed reduction or elimination tumor growth (Pittoni, 
Tripodo et al. 2011).  An additional study demonstrated that combining Cromolyn 
with Gemcitabine, a drug typically used to treat pancreatic cancer, enhance the 
effects of Gemcitabine to reduce tumor growth in pancreatic mouse models 
(Arumugam, Ramachandran et al. 2006).   
 Since, mast cells are essential in tumor formation we postulate that the 
inhibition of mast cell may reduce tumor counts as well as reduce the potential 
recurrence post therapy. Thus, ideally utilizing a pharmacological drug such as, 
Cromolyn that inhibits the degranulation of mast cells in combination with 5-FU 
therapy should be beneficial to treat colon cancer. We sought to determine if 
administration of Cromolyn post 5-FU therapy would hinder tumor development, 
and prolong the anti-tumor effects of 5-FU therapy. Results indicates that a 
synergistic effect does occur with the addition of Cromolyn post 5-FU therapy, 
however, additional studies are necessary to analyze the mechanistic effects to 
truly determines if this treatment has a prolong effect.   
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4.3 MATERIALS AND METHODS: 
Treatment Schedules 
 Six week old ApcMin/+ mice were subjected to systemic treatment with 5-FU 
(40 mg/kg) for five weeks with one week intervals between three treatment 
weeks. Mice treated with a combination of 5-FU and Cromolyn (10 mg/kg) 
determined the effect of mast cell inhibition on tumor burden, response to 
therapy, and recurrence post therapy. Illustrated below (Figure 4.1), 
administering Cromolyn occurred in weeks 7 and 9, with 5-FU administered 
during weeks 6, 8, and 10. The Cromolyn treatment then resumed for the 6 
 
Figure 4.1: Mast cells chemotherapy regimen.  Chemotherapy schedules for 5-FU, 
Cromolyn, and 5-FU+ Cromolyn administration for the non – tumor recovery groups 
(blue box), and for the tumor recovery groups (purple box). PBS (control group) is 
administrated during the duration of the chemotherapy schedules. 
 
50 mg/kg 5-FU
(I.p. injections)
10mg/kg Cromolyn
(I.p. injections)
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weeks after the 5-FU therapy (Figure 4.1).  Mice treated with PBS, Cromolyn, or 
5-FU alone served as the controls.  
Tissue collection, Tumor Scoring, and Granulocytes staining 
 ApcMin/+ mice were humanely sacrificed at the end of the treatments either 
at 10 or at 16 weeks by cervical dislocation. Collecting the small intestines and 
colon require cleaning by flushing with PBS, cutting open longitudinally, and 
fixing in 4% paraformaldehyde overnight. This prepares the fixed tissues for 
tumor scoring or histological analysis. For tumor, scoring fixed tissue requires 
staining in 0.002% methylene blue in PBS pH 7.4 for visualization of the tumors 
with a dissecting microscope. Tumors were classified as being greater or less 
than 1mm in diameter with an ocular micrometer.  For histological analysis fixed 
tissues was Swiss-rolled and embedded in paraffin cassettes and left to dry 
overnight.  Slices from the embedded paraffin cassettes (3-5 micron) form 
sections, which are mounted on standard microscopy slides coated with poly-L-
lysine. The Instrumentation Resource Facility (University of South Carolina 
School of Medicine) conducted the histological preparation of the fixed tissue.  
Histochemical staining of the tissue sections for mast cells was achieved by 
keeping with the manufacturer protocol, using naphthol-AS-D chloroacetate 
esterase (kit obtained from Sigma). 
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4.4  RESULTS: 
4.4.1 Tumor response and granulocytes migration to the addition of 
Cromolyn during 5-FU therapy 
 To determine tumor response to the effect of adding Cromolyn during the 
weeks when 5-FU is not administered to ApcMin/+ mice. These animals underwent 
this alternative treatment schedule from six to ten weeks of age. PBS, 5-FU, and 
Cromolyn groups were used as control groups. Tumor burden for the intestines 
of these animals indicate that the addition of Cromolyn during the off weeks of 5-
 
Figure 4.2: Tumor analysis from ApcMin/+mice subjected to therapy with no 
recovery. a. .Intestinal sections stained with methylene blue from three mice in the 
treatment groups with no recovery from the chemotherapy regimen.  b. Tumor burden in 
ApcMin/+mice subjected to therapy with no recovery. Tumor burden in mice treated with 
5-FU or 5-FU/CR indicated a significant decrease in tumor burden as compared to the 
PBS-treated group (p=0.015 and p= 0.007, respectively).  Treatment with Cromolyn 
alone did not reduce tumor burden. c. Number of tumors that are less than 1 mm in size 
in mice treated with 5-FU, Cromolyn, or 5-FU and Cromolyn with no recovery. d. 
Number of tumors that are greater than 1 mm in size in mice treated with 5-FU, 
Cromolyn, or 5-FU and Cromolyn with recovery. Tumor size in mice treated with 5-FU 
and 5-FU/CR were significantly smaller when compared to those in mice treated with 
PBS (p=0.0094 and p=0.0020 respectively). 
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FU treatment does significantly reduce tumor number compared to the PBS 
treated animals. In addition promising results show that tumor numbers in the 5-
FU/CR group is slightly lower than the animals that were subject to 5-FU alone 
(Figure 4.2b). When scoring the tumors by size both 5-FU and 5-FU/CR groups 
indeed inhibit regression of tumor development, for both these groups had less 
number of tumors measure greater than 1mm compared to the PBS animals, yet 
the 5-FU/CR treatment was slightly better than the 5-FU alone (Figure 4.2 d). 
These results suggest that a synergetic response is occurring by administer 
Cromolyn during the alternative weeks of 5-FU treatment. Conversely, in 
analyzing the tumor response in the animals treated with Cromolyn alone we 
 
Figure 4.3: Infiltration of mast cells and granulocytes in intestinal tissue from 
ApcMin/+mice subjected to therapy with no recovery. a. Localization of mast cells 
and granulocytes by histochemical staining of intestinal tissues from treated mice with 
no recovery using naphthol-AS-D chloroacetate esterase.  Mast cells and granulocytes 
are highly abundant in the peripheral regions of tumors from mice treated with PBS, 5-
FU, and Cromolyn. Mast cells are not observed in tumors from mice treated with a 
combination of 5-FU and Cromolyn.  b. Quantification of mast cells and granulocytes in 
tumor regions of treated mice without recovery after chemotherapy. There is significant 
difference between treatment with 5-FU and 5-FU/CR (p=0.0192 and p=0.0135, 
respectively) as compared to treatment with PBS. 
 
PBS 5-FU/CR5-FU Cromolyn
10X
40X
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observe an increase in tumor burden as well as an increase of the tumors that 
are greater than 1mm when comparing to all of the other treatment groups 
(Figure 4.2). This data indicates the Cromolyn alone is not able to inhibit 
regression or the multiplicity of tumor development or growth in ApcMin/+ mice. 
Upon histochemical analysis, infiltration of granulocytes and mast cells into the 
tumor occurs more frequently in the Cromolyn treated animals than the 5-FU or 
5-FU/CR animals and appears to be similar to the PBS animal. This data suggest 
that 5-FU is either prohibiting the maturation of these cells for which then 
influencing these cells ability to infiltrate into the tumor or just influences the 
infiltration of these cells into the tumor for the environment is alter by the 
treatment, and therefore these cells are not recruited (Figure 4.3). The addition of 
Cromolyn during 5-FU treatment demonstrated promising results, however, 5-FU 
treatment alone as shown to be promising, however once treatment is ceased 
tumor recurrence is problematic. Thus, we examine tumor response to 
administering Cromolyn post 5-FU therapy.  
4.4.2 Tumor response and granulocytes migration to the addition of 
Cromolyn post 5-FU therapy 
To determine tumor response to the effect of adding Cromolyn post 5-FU 
therapy in ApcMin/+ mice. These animals underwent this treatment therapy from 
six to fifteen weeks of age, for which the tenth up to the fifteenth week of age 
represent the period of treatment recovery. PBS, 5-FU, and Cromolyn groups 
were again used as control groups. Tumor burden for the intestines of these 
animals indicate that the addition of Cromolyn post 5-FU treatment does 
significantly reduces tumor number compared to both the PBS and 5-FU treated 
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animals (Figure 4.4b). Also from these result it is important to indicate that we did 
not observe any significant difference when comparing the PBS with 5-FU 
treated animals, indicating that rebound of tumor growth occurred during the 
period of recovery. Thus, the addition of Cromolyn post 5-FU therapy further 
suggests promising effects in inhibiting tumor growth. This implication is further 
validated when tumor scoring of size is analyzed and results show that there is a 
statistical reduction of the number of tumor, which are greater than 1mm in the 
 
Figure 4.4: Tumor analysis from ApcMin/+mice subjected to therapy with recovery. 
a.Intestinal sections stained with methylene blue from three mice in the treatment 
groups with recovery from the chemotherapy regimen.  b. Tumor burden in ApcMin/+mice 
subjected to therapy with recovery. Tumor burden in mice treated with 5-FU-CR-R 
caused a significant decrease in tumor burden as compared to the PBS-treated group 
(p=0.0009). There is a significant decrease in tumor burden in mice that were treated 
with 5-FU and Cromolyn with recovery as compared to mice treated with 5-FU alone 
and allowed to recover.  The mice treated with Cromolyn alone did not show a 
decrease in tumor burden.c. Tumor counts for which the size is less than 1mm for each 
treatment groups for the recovery regimen. d. Tumor count sizes that is greater than 
1mm for each treatment groups in the recovery regimen. Tumor sizes for groups 5-FU 
and 5-FU-CR-R (p=0.0469 and p=0.0001 respectively) were significantly smaller when 
compared to PBS tumor sizes.  
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intestines of animals treated with 5-FU and Cromolyn during the recovery period 
in comparison to the PBS and 5-FU animals (Figure 4.4d). These results 
indicates that a synergetic response does occurring by administer Cromolyn post 
5-FU treatment, by assisting in the inhibition of tumor regression.  
Again in opposition,  animals treated with Cromolyn alone we observe an 
increase in tumor burden as well as an increase of the tumors that are greater 
than 1mm when comparing to all of the other treatment groups (Figure 4.4). This 
data reiterates that Cromolyn alone is not able to inhibit regression or the 
 
 
Figure 4.5: Infiltration of mast cells and granulocytes in intestinal tissue from 
ApcMin/+mice subjected to therapy with recovery. a. Localization of mast cells and 
granulocytes by histochemical staining of intestinal tissues from treated mice with 
recovery from therapy using naphthol-AS-D chloroacetate esterase. Mast cells and 
granulocytes were highly abundant in the peripheral regions of the tumor.  b. 
Quantification of mast cells and granulocytes in tumor regions of treated mice that were 
allowed to recover from chemotherapy. There is a significant difference in mice treated 
with the 5-FU-CR-R regimen as compared to mice treated with PBS (p=0.0041).  
 
 
 
 
 
Figure 5.5: A. Localization of mast cells and granulocytes by histochemical staining of 
PBS-R 5-FU-R CR-R+CR
10X
40X
5-FU-R+CR
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multiplicity of tumor development or growth in ApcMin/+ mice. In addition, 
histochemical analysis, confirms more infiltration of granulocytes and mast cells 
into the tumor of the Cromolyn group than the animals treated with PBS, 5-FU or 
5-FU/CR. The increase influx of granulocytes seen only in the Cromolyn treated 
animals suggests that Cromolyn is influencing either the maturation or function of 
these particular cells (Figure 4.5). This is important to understand so that we may 
better understand the synergetic response that is occurring when adding 
Cromolyn post 5-FU treatment in ApcMin/+ mice.   
4.4.3 Systemic response to the effects to Cromolyn treatment  
 To determine the influence of Cromolyn on granulocytes maturation and 
function, collection of serum from mice prior and after treatment is analyze to 
determine the systemic levels of various cytokines and chemokines by a 
multiplex or an ELISA assays. The multiplex analysis allowed evaluation of many 
cytokines and chemokines in one assay (data not shown); however, most 
relevant are the results from the analysis of the granulocyte colony-stimulating 
factor, which warned attention for it correlates with the previous observation of 
increase infiltration of granulocyte in the tumor region of those mice treated with 
only Cromolyn. Shown in figure 4.6a we observe higher systemic levels of G-
CSF only in mice subjected to Cromolyn compared to the other treatment 
regimen. Implicating that Cromolyn is indirectly influence the maturation of bone 
marrow cells into granulocytes by elevating the systemic levels of G-CSF. Yet, in 
examining, the systemic histamine levels of each treatment group, results do not 
show any significant difference (Figure 4.6b). Histamine levels do not appear to 
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decrease from the addition of Cromolyn, suggesting either that mast cells are not 
sufficiently inhibit by Cromolyn effects, or that other immune cells are 
compensating for the lack of histamine released, due to mast cell inhibition by 
Cromolyn. The latter of the two explanations seem more plausible, for clear 
Cromolyn is affecting other immune cells maturation and function as previous 
described.  
4.5 DISCUSSION: 
 The data suggests that administration of Cromolyn during recovery lessen 
tumor multiplicity possibly by interfering with the regrowth of residual tumors for 
the tumor sizes were significantly smaller in mice subjected to Cromolyn post 5-
FU therapy. However, even though these results are promising in sustaining 
regression of the tumor development, there are hesitations in consider Cromolyn 
 
Figure 4.6: Serum levels of G-CSF and histamine. a. Serum levels of granulocyte 
colony stimulating factor were measure by multi-plex assay. Concentration of G-CSF is 
highly elevated in mice treated with CR-CR-R regimen. b. Serum levels of histamine in 
mice subjected to chemotherapy followed by recovery. Serum samples were obtained 
prior to treatment (pre-bleed, PB) and after treatment (final-bleed, FP).  ELISA determined 
levels of histamine in serum samples. 
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the appropriate drug choice for sustaining tumor regression. Solely evaluated 
animals treated with Cromolyn alone, results show a significant increase of 
tumors multiplicity and the inability of Cromolyn to inhibit the progression of tumor 
development. In actuality, Cromolyn appear to encourage tumor genesis in the 
ApcMin/+ mice model, for the tumors drastically larger and highly vascularized. 
These results were alarming and contrary to previous studies that have indicated 
that Cromolyn mitigates tumor progression (Soucek, Lawlor et al. 2007; Pittoni, 
Tripodo et al. 2011). A plausible explanation for contradicting results is the 
differences in mouse models and the type of cancer examine to evaluate the 
effects of Cromolyn.  Despite, the differences in results the data from this study is 
insightful, such that Cromolyn, is consider a mast cells stabilizer; and by affecting 
the function of mast cells we potentially influence the function of other immune 
cells, thus causing a negative effect. This increase progression of tumor 
development coincides with a study that demonstrates that the ablation of mast 
cells in ApcMin/+ mice also results in the increase of tumor burden and size when 
compared to littermates (Sinnamon, Carter et al. 2008). In addition, this particular 
study observed that ablation of mast cells resulted in a significant decrease influx 
of tumor infiltrating eosinophils and a slight increase of neutrophils. Theses 
evidences can implicate that during tumor development mast cells exhibits 
protective properties, by means of influencing the function or migration of other 
immune cells into the tumor, to assist with the inhibition of tumor progression.  
Therefore, in accordance with the result observed by the animals treated only 
with Cromolyn, mast cells protective role of influencing other immune cells may 
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be disrupted, resulting in deficiency regulation of immune cells and the high 
infiltration of granulocytes cells within the tumor to compensate for the lack of 
mast cell activity. This high influx of granulocytes can potentially be the 
contributing factor to the expansion of tumor burden observed in the Cromolyn 
only treated animals.  
Indeed, we did not observe any statistically difference in systemic levels of 
histamine for any of the treatment groups, thus unable to validate mast cell 
inhibition. Nonetheless, we have no inclination to suggest that Cromolyn failed to 
inhibit mast cells degranulation in this model, but incline to say that the inhibition 
effects were not observed. For we only examined the level of systemic histamine 
only at the beginning and end of any drug treatment. The longevity of Cromolyn’s 
affect and the mechanism for which it inhibits mast cells is poorly understood. It 
is state to inhibit mast cells by indirectly inhibiting the influx of chloride ion across 
the cell membrane to assist with the activation of degranulation. The 
generalization of Cromolyn effects can indeed influence the function of other cell 
type if not all cell type. Several studies have observed Cromolyn’s effect on other 
cell types, for instance, an in-vitro study showed that pre-incubation of human 
neutrophils, monocytes, and eosinophil with Cromolyn resulted in inhibits the 
activation of these cells in response to synthetic bacterial analogue (Kay, Walsh 
et al. 1987). In addition, Cromolyn has been shown to inhibit the migration of 
eosinophil (Bruijnzeel, Warringa et al. 1990). Another study shows Cromolyn 
ability to inhibit the function of chloride channels on epithelial intestinal cell line 
HT29 (Reinsprecht, Pecht et al. 1992). Thus, further studies need to be perform 
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to determine the effect of Cromolyn on cells in the microenvironment to assess 
its potential as a therapeutic agent that can be used synergistically with 5-FU to 
enhance anti-tumor effects of prolong tumor recurrence post therapy. 
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  CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The progression of cancer is a multi-step process, for which cells undergo 
several mutations, and the development of colorectal cancer is no exception. 
One of the many painstaking events of tumorigenesis has been underlining the 
involvement and the function of the tumor microenvironment. The TME 
comprised of non-neoplastic cells derived from the hematopoietic system; and 
ironically, some of these non-neoplastic cells exhibits characteristics, which 
promotes and assist with tumor development. This multifaceted interaction 
between cancer cells and the non-neoplastic cells within the TME influences both 
the progression of the tumor, and how the tumor responds to chemotherapy. 
Hence, the efficacies of chemotherapies are reliant on the responsiveness of 
both neoplastic and non-neoplastic cells. 
For decades, the focus of chemotherapy drugs was design to target 
neoplastic cells, for tumors was perceived to be a composition of highly 
proliferative neoplastic cells. A prevalent drug used in the past and present to 
treat colorectal cancer and other cancers is 5-Fluorouracil. This drug has been 
effective for it inhibits the catalytic function of the enzyme Thymidylate Synthase. 
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TS is highly expressed in cells that are proliferating, and neoplastic cells are 
highly proliferative, thus the efficacy of 5-FU is promising in treating cancer. 
However, the pitfalls of using this drug are its systemic cytotoxic side effects, due 
to its lack of specificity; and the reoccurrence of cancer after treatment. Thus, to 
circumvent these shortcomings we developed and examined the effects of two 
therapeutic strategies that would target both neoplastic and non-neoplastic cells 
in the TME to enhance 5-FU effectiveness and reduce its cytotoxicity. 
The first therapeutic strategy involved lessening the levels of TS in 
BMDCs that infiltrates and establishes the TME. The postulation of this 
therapeutic strategy evolved from  previous studies that demonstrated 
reprogramming BMDCs to expressed E.coli TS, a resistant phenotype decreased 
the efficacy of 5-FU in tumors. The implications from these studies suggested 
that reprogramming the protein expression in cells influences response to 
chemotherapy. Conversely, reprogramming cells to express lesser levels of TS 
should enhance 5-FU efficacy. To accomplish reduction of TS protein, RNA 
interference technologies were used to inhibit the translation of TS mRNA, and 
results showed an increase of cellular sensitivity to 5-FU. However, troublesome 
results were observed in our first attempts to used genetic modified BMDCs. 
These troublesome results stress the importance of using an appropriate RNAi 
model system, especially if this particular therapy becomes applicable for treating 
cancer in humans. 
Eventually we obtain an appropriate RNAi vector system, which permitted 
us to examine the effects of modulated BMDCs in the tumor of the subcutaneous 
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CT26 cancer mouse model. In addition, the identity of a non-cytotoxic RNAi 
vector system we confirm that the OPN promoter has inducible characteristics 
that are only functional in pro-inflammatory environments, such as the TME.  
Additionally, the OPN promoter has the aptitude to drive the expression of an 
RNAi sequence against TS to establish enhance sensitivity to 5-FU therapy. 
Although we obtain the essential components to establish tumor specific chemo-
sensitivity our results were not significant, and therefore we are unable to 
confidently conclude that this therapeutic application is beneficial.  Nevertheless, 
with additional studies describe in Chapter 4 are performed this therapeutic 
strategy could be utilized to modulate the expression of various proteins in 
BMDCs which infiltrates the tumor. Thus, essential our studies are just the 
beginning in providing insight to improve this therapeutic strategy. Future studies 
from this therapeutic strategy could involve reducing expression of VEGF, TGF-
beta, HGF and other pro-tumorigenic proteins, or at best increase the expression 
of anti-tumorigenic proteins. After more scrutiny and investigation, the ability to 
modulate the protein expression of BMDCs that infiltrates the TME could disrupt 
pro-tumorigenic functionality of these cells, and provide several avenues of 
therapy. 
On the other hand, incorporating additional pharmacological drugs which 
targets specific BMDCS with current therapies can also potential beneficial in 
reducing tumor growth and reducing reoccurrence after therapy. In our case, the 
administration of Cromolyn to inhibit the function of mast cell in conjunction with 
5-FU therapy did indeed reduce tumor growth and reoccurrence. However, not 
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fully understand the mechanistic effect of Cromolyn we were unable to conclude 
the longevity of therapeutic application would be beneficial. Thus, with additional 
studies examining the effects of Cromolyn on other BMDCs will be beneficial in 
determine if this l drug is appropriate to use in combination with 5-FU to prevent 
reoccurrence of tumors. Additionally, the kinetics of Cromolyn effects within the 
tumor needs to be investigated to determine if prolong usage of this drug is 
beneficial in combination with 5-FU therapy.  
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